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Cisplatin is a major therapeutic drug for solid tumors, but can cause severe 
nephrotoxicity. This not only compromises the usage of cisplatin in the 
therapy of cancer but also aggravates patients’ state of illness. However, 
strategies for tackling the clinical problem are largely lacking. The current 
study aimed to investigate the role and therapeutic potential of hydrogen 
sulfide (H2S), an endogenous gaso-transmitter, in cisplatin nephrotoxicity. 
Moreover, the therapeutic potential of hydrogen polysulfide, a novel H2S 
derived signalling molecule, was also examined in the disease.  
This study provided a comprehensive understanding about the role and 
therapeutic potential of H2S in cisplatin nephrotoxicity. The results in the 
present study showed that cisplatin led to the reduction of endogenous H2S by 
downregulating the expression of H2S producing enzyme cystathionine γ-lyase 
(CSE), which may be involved in the following renal proximal tubule (RPT) 
cell death and nephrotoxicity. Furthermore, H2S donors like NaSH and 
GYY4137 ameliorated cisplatin caused renal toxicity in vitro and in vivo 
probably through suppressing the activation of NADPH oxdiase, downstream 
reactive oxygen species (ROS) generation and mitogen-activated protein 
kinases (MAPKs) activation. Importantly, GYY4137 not only ameliorated 
cisplatin caused renal injury but also added on more anti-cancer effect to 
cisplatin in cancer cell lines. These results suggest that H2S may be a novel 
target for cisplatin nephrotoxicity. 
Thereafter, the therapeutic potential of hydrogen polysulfide, a novel H2S 
derived signaling molecule, was also examined. The results showed that 
xv 
 
polysulfide donor Na2S4 ameliorated cisplatin caused renal toxicity in vitro 
and in vivo through suppressing intracellular ROS generation and downstream 
MAPKs activation. Additionally, polysulfide may inhibit ROS production by 
lessening the activation of NADPH oxidase and induction of Nrf2 nucleus 
translocation simultaneously in RPT cells. Importantly, polysulfide not only 
ameliorated cisplatin caused renal injury but also added on more anti-cancer 
effect to cisplatin in non-small cell lung cancer (NSCLC) cell lines. 
Additionally, the results also showed that the number of sulfur atoms in 
polysulfide well reflects the efficacy of these molecules not only in cell 
protection but also cancer inhibition which may serve as a guide for further 
development of polysulfide donors for pharmaceutical usage.  
Taken together, the present study provides a novel pharmacological usage of 
H2S or polysulfide in cisplatin nephrotoxicity by leveraging their cell 













Chapter I Introduction 
 
1.1 An overview of hydrogen sulfide  
Hydrogen sulfide (H2S)  has been regarded as a toxic gas for hundreds of years 
[1]. It can directly inhibit the activity of several essential enzymes in humans 





 ATPase [2], thereby causing toxicity. However, the image of 
H2S has been largely expanded since the revelation of H2S as an endogenous 
neuronal modulator by Abe and Kimura in 1996 [5]. Thereafter, the 
physiological significance of H2S has been extensively studied in various 
mammalian systems [6, 7]. Now, it is recognized as the third gaseous 
transmitter alongside nitric oxide (NO) and carbon monoxide (CO) in 
mammals [8].  Herein, recent studies regarded H2S are reviewed with 
emphasis on its roles in renal system and cancer biology.  
1.1.1 Physical and chemical properties of H2S 
H2S exists as a colorless gas with a strong rotten egg smell at room 
temperature and ambient pressure. The human nose can detect a concentration 
of 400-fold lower than its toxic level [9], whereas long term exposure can 
cause desensitization of olfactory nerves to H2S [10]. Distinct from the other 
gaseous transmitters like NO and CO, H2S is a weak acid and hence able to 
readily dissolve in water. Based on its PKa values, it is estimated that there 
will be 14% H2S gas, 86% HS
-
 and a trace of S
2-
 in plasma (pH 7.4), while 
there will be 50% H2S gas and 50% HS
-
 in cytosol where pH value is 7.0 [10]. 
In the thesis, we follow the tradition of using H2S to indicate all three species 
unless specified. Moreover, H2S gas is highly lipophilic which allows it to 
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freely penetrate into the cell membrane of all types and become biologically 
active [11].  
Sulfur is a versatile atom with multiple oxidation states ranging from -2 to +6. 
In H2S, the oxidation state of sulfur is -2; therefore, it can act as a reductant 
and only be oxidized. In line with this, accumulative evidence suggests that 
H2S actively takes part in three types of reactions in mammalian systems, 
including (1) interaction with the reactive oxygen species (ROS) or reactive 
nitrogen species (RNS) [12-14]; (2) reduction of the protein irons namely the 
metal center on proteins; and (3) transformation of protein R-SH group into R-
SSH group, a process called S-sulfhydration [11]. For a thorough description 
of the chemical basis of these interactions, it is advised to refer to Li and 
Lancaster’ recent review on the chemical foundation of H2S biology [15].  
1.1.2 Biosynthesis and catabolism of H2S 
1.1.2.1 Biosynthesis of H2S 
The first description of H2S production in life can be retrieved back to 1895 in 
bacteria [16]. One hundred years later, the detection of sulfide was firstly 
reported in brain tissues [17] and later in other mammalian systems [18, 19]. 
Distinct from bacteria, mammalian cells mainly rely on enzymatic pathways to 
generate H2S, although nonenzymatic pathways are also responsible for a 
small portion of the production. By using enzymatic system, H2S production 
can be regulated tightly and precisely in mammalian cells. Four enzymatic 
pathways have been discovered which are responsible for endogenous H2S 
biosynthesis, including cystathionine β-synthase (CBS), cystathionine γ-lyase 
(CSE), 3-mercaptopyruvate sulfurtransferase (3MST) coupled with cysteine 
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aminotransferase (CAT), and 3MST coupled with peroxisome located D-
amino acid oxidase (DAO). Among these enzymes, CBS and CSE are 
pyridoxal 5’-phosphate (PLP) dependent enzymes mainly located in cytosol. 
They are able to catalyze L-cysteine into H2S in the absence or presence of 
homocysteine. In contrast, 3MST is PLP independent and mainly resides in 
mitochondria. It produces mitochondrial H2S using 3-mercaptopyruvate (3MP) 
as a substrate which is derived from L-cysteine and D-cysteine by CAT and 
DAO respectively. The synthetic processes of H2S by these enzymes are 















Figure 1-1: Endogenous synthesis of H2S by four pathways in renal system. 1. 
CBS mediated H2S synthesis with L-cysteine as the substrate in cytosol; 2. CSE 
mediated H2S synthesis with L-cysteine as the substrate in cytosol; 3. CAT 
transforms L-cysteine into 3MP which is further catalyzed by 3MST into H2S in 
mitochondria; 4. Peroxisome resident DAO catalyzes D-cysteine into 3MP which is 
then exchanged into mitochondria and utilized by 3MST for the production of H2S 
in mitochondria. CBS: cystathionine β-synthase; CSE: cystathionine γ-lyase; 3MST: 
3-mercaptopyruvate sulfurtransferase; CAT: cysteine aminotransferase; DAO: D-
amino acid oxidase; 3MP: 3-mercaptopyruvate. 
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1.1.2.1 Catabolism of H2S 
Along with the production of endogenous H2S, it has to be disposed very 
quickly as the accumulation of H2S may lead to organ toxicity. In comparison 
with the biosynthesis of H2S, the catabolism of this gaseous transmitter is not 
well studied and most of evidence was obtained by using exogenous H2S [20]. 
Therefore, further validation is needed under experimental settings of 
physiological conditions. Currently, three pathways have been suggested to 
engage in the disposal of H2S in mammals. Mitochondrial oxidation is the 
main pathway universally present in various tissues [21]. Briefly, H2S is firstly 
converted into persulfides by a mitochondrial enzyme named sulfur quinine 
oxidoreductase (SQR). The formed persulfides are further catalyzed into 
excretable form of sulfate [22]. Besides, H2S can also be oxidized by non-
mitochondrial heme proteins like myoglobin and hemoglobin into excretable 
products [23, 24]. To a less extent, ROS and RNS are able to directly interact 
with H2S. As a result of these efficient mechanisms for H2S catabolism, the 
concentration of free H2S is normally kept very low in mammals  [21]. 
1.1.3 H2S in renal system 
1.1.3.1 H2S producing enzymes in kidney 
H2S generation is abundant in kidney given the presence of all the above 
mentioned pathways in the organ (Figure 1-1). Currently, it is believed that 
CSE and CBS are the dominant enzymes for H2S generation in kidney.  The 
presence of these two enzymes was firstly demonstrated in 1980s by using 
their inhibitors [25]. Later on, House et al. [26] found that both enzymes were 
mainly located on renal proximal tubules within the renal cortex by 
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comparison with marker enzymes of known location. This finding was 
supported by several other studies using different methods [27-29]. However, 
inconsistent results have been reported regarding the existence of these two 
enzymes in glomerulus which needs to be resolved [30-32]. Additionally, 
definitive evidence has suggested the presence of 3MST in kidney [30, 33-35]; 
however, the significance of 3-MST mediated H2S generating pathway has not 
been well acknowledged in both kidney physiology and diseases due to 
limited reports.  
1.1.3.2 H2S in renal physiology 
1.1.3.2.1 Effect of H2S on renal excretory function 
The necessity of H2S producing enzymes have long been recognized in the 
kidney due to their critical effect on homocysteine metabolism [36]; however, 
the effect of H2S itself on renal function was not studied until recently (Figure 
1-2A). Intra-renal infusion of H2S donor NaSH is able to increase glomerular 
filtration rate (GFR), urinary sodium (UNa·V) and potassium (Uk·V) 
excretion [37, 38]. Moreover, these effects are all mimicked by the infusion of 
L-Cysteine, an H2S generating substrate [37]. In addition, inhibition of 
endogenous H2S production by aminooxyacetic acid (AOAA, CBS inhibitor) 
plus DL-propargylglycine (PAG, CSE inhibitor) leads to the decrease of GFR, 
UNa·V and Uk·V, suggesting that H2S regulates renal function at 
physiological conditions. However, either AOAA or PPG alone fails to 
produce any effect on renal function, implicating a compensatory effect 
between CBS and CSE on renal regulation which has been later confirmed by 
another study [39]. Hypothesis concerning the effects of H2S on sodium 
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transporters was formed and tested thereafter. The results showed that H2S 











 ATPase (NKA) which may account for its effect on renal function. 
Recently, the mechanism underlying the inhibitory effect of H2S on NKA was 
studied by Zhu’s group [38]. In the study, they showed that NaSH promoted 
NKA endocytosis by directly activating epidermal growth factor receptor 
(EGFR) in renal tubular epithelial cells.  
1.1.3.2.2 Effect of H2S on renin release 
The renin-angiotensin system (RAS) is a renovascular hormone system 
involved in the regulation of plasma sodium concentration and blood pressure. 
Renin release from juxtaglomerular (JG) cells determines RAS activity and the 
process is known to be regulated by intracellular cAMP [40-42]. Moreover, 
H2S was reported to downregulate cAMP level in several cell types [43, 44], 
implying that H2S may modulate renin release. This was demonstrated by our 
group in 2010 [45]. It was found that NaSH inhibited the upregulation of renin 
mRNA and protein level in a model of renovascular hypertension 
accompanied by a reduction of intracellular cAMP level. This is supported by 
another study [46] showing that H2S regulates renin degranulation in As4.1 
and rat renin-rich kidney cells stimulated by isoproterenol, forskolin or 3-
isobutyl-1-methylxanthine. In the same study, it was demonstrated that H2S 
significantly suppressed the stimulated adenylate cyclase (AC) activity in 
these cells. Overexpression of H2S producing enzyme CSE also attenuates 
isoproterenol-induced renin release, suggesting that endogenous H2S may also 
involve in the process. However, the mechanism underlying the inhibitory 
effect of H2S on AC remains to be determined, such as the identification of 
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AC isoform(s) accounting for H2S effect and the molecular interaction 
between H2S and the AC isoform(s). Besides AC, ROS was recently reported 
to be a target of H2S for its effect on renin reduction in diabetic nephropathy 
(Figure 1-2B), suggesting participation of multiple mechanisms in the process 
[47].  
1.1.3.2.3 H2S as an O2 sensor in the kidney 
Essentially all H2S generation is independent of O2; however, metabolism of 
H2S is a process highly relying on O2 [48].  Accumulating evidence suggests 
that H2S is an O2 sensor in kidney, especially in renal medulla (Figure 1-2C).  
The availability of O2 in renal medulla is lower compared with that in renal 
cortex which results in a higher abundance of H2S in this region [49]. Provided 
mitochondria can use H2S as an electron donor for ATP production [50, 51], it 
will be interesting to hypothesize that H2S might be a direct source of energy 
in renal medulla. During hypoxia, O2 reduction leads to further accumulation 
of H2S which helps to recover O2 supply by increasing medullary blood flow 
and inhibition of tubular transport [52]. In addition, CBS and CSE can 
translocate into mitochondria and stimulate H2S production under hypoxic 
circumstances [50, 51]. The mitochondria derived H2S may directly participate 
in ATP production. Currently, emerging physiological evidence for H2S 
mediated O2 sensing has also been suggested in various O2 sensing tissues 
including cardiovascular system [53, 54], respiratory system [55], 
gastrointestinal tract [56] et al. However, the downstream effectors of H2S 




1.1.3.3 H2S in acute kidney injury 
Acute kidney injury (AKI) is defined as a syndrome characterized by a rapid 
loss of kidney’s excretory function. It is the clinical manifestation of several 
disorders that affect the kidney acutely [57]. Herein, effects of H2S on two 
types of AKI are discussed namely renal ischemia/reperfusion injury (IRI) and 
obstructive nephropathy. 
1.1.3.3.1 H2S in renal ischemia/reperfusion injury  
 
Figure 1-2: Effects of H2S on renal regulation. (A) H2S inhibits the activity of tubular 
NKCC and NKA, thereby enhancing renal excretory function such as GFR, UNa.V and 
Uk.V.  (B) H2S suppresses renin release by inhibition of AC activity and ROS 
production in GC cells. (C) H2S as an O2 sensor in the kidney. In normoxic condition, 
H2S is metabolized into sulfates in the presence of O2; In hypoxic condition, the 
shortage of O2 leads to the accumulation of H2S which helps to restore O2 level by 











 ATPase; GFR: glomerular filtration rate; 
UNa·V: urinary sodium; Uk·V: urinary potassium; β1: β1-adrenoceptor; ROS: reactive 
oxygen species; ATP: Adenosine triphosphate; cAMP: Cyclic adenosine 




Renal IRI is a major cause of acute kidney injury. The pathophysiological 
mechanism underlying renal IRI is very complex which may contain ATP 
depletion, calcium overload, ROS generation, apoptotic and inflammatory 
responses et al [58]. The engagement of endogenous H2S in renal IRI has been 
thoroughly demonstrated in various studies [59, 60]. Specifically, both mRNA 
and protein levels of CSE and CBS are apparently reduced upon IRI along 
with the reduction of H2S level in kidney and plasma [59, 60], although 
mechanisms underlying IRI caused CSE and CBS reduction remain elusive. In 
addition, inhibition of either CSE or CBS by their pharmacological inhibitors 
severely aggravates renal damage [60, 61], indicating that the ischemic renal 
injury might partially result from the impaired endogenous production of H2S. 
The implication is supported by a recent finding that CSE-deficiency 
associates with increased renal damage and mortality after renal IRI [31]. 
Subsequently, the effect of exogenous H2S was extensively studied in various 
renal IRI scenarios [29, 31, 59-67].  In most studies, an H2S donor, NaSH, was 
employed and elicited protective effects likely through anti-inflammatory, 
anti-apoptotic and anti-oxidant responses. Comparing with new generation 
synthetic H2S donors like GYY4137, NaSH is less physiologically accurate 
H2S producer [68, 69]. Recently, GYY4137 was shown to attenuate heart 
damage by inhibiting activation of Nuclear factor-κB (NF-κB) and mitogen-
activated protein kinase (MAPK) signaling in a rat model of myocardial IRI 
[70, 71].  Thus, studies are warranted to study whether slow H2S donors like 
GYY4137 can protect kidney form IRI. Besides, it is worth noting that AP39, 
a mitochondrially targeted donor of H2S, was recently found to inhibit 
intracellular ROS formation caused by glucose oxidase and protect kidney 
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from IRI caused damage in rats [67]. Taken together, these data implies a 
promising strategy by targeting H2S to treat renal IRI. 
1.1.3.3.2 H2S in obstructive nephropathy 
Obstructive nephropathy is a type of renal injury caused by obstruction of the 
genitourinary tract. Renal fibrosis after ureteral obstruction is implicated in the 
development of obstructive nephropathy [72]. Hu and others showed that 
ureteral obstruction impaired endogenous production of H2S by reducing the 
expression level of CBS [73]. Renal fibrosis is attenuated when exogenous 
H2S is administered, suggesting an inhibitory effect of H2S on renal fibrosis 
[73]. In cultured kidney fibroblasts, NaSH is able to inhibit cell proliferation 
and block the differentiation into myofibroblasts by suppressing transforming 
growth-β1-Smad and MAPK signaling pathways [73]. Furthermore, 
administration of NaSH also prevents renal dysfunction caused by ureteral 
obstruction [73-75]. A recent study from Sener’s group [76] showed that H2S 
slowly releasing donor GYY4137 mitigated cortical loss, inflammatory 
damage and tubulointerstitial fibrosis in a rat model of obstructive 
nephropathy. Taken together, these results suggest a potential use of H2S 
donor as a rescue in obstructive nephropathy.  
1.1.3.4 H2S in chronic kidney disease 
Chronic kidney disease (CKD) is a general term for heterogeneous disorders 
affecting kidney structure and function. In western countries, it is generally 
associated with old age, diabetes, hypertension, obesity and cardiovascular 
disease [77]. Diabetic nephropathy and hypertensive nephropathy are 
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considered as presumed pathological entities. The role of H2S in these two 
types of chronic kidney disease is reviewed below. 
1.1.3.4.1 H2S in diabetic nephropathy 
Diabetic nephropathy (DN) is the number one leading cause of chronic kidney 
disease in western countries. Morphologically, DN is characterized by 
hypertrophy induced kidney growth and excessive accumulation of 
extracellular matrix proteins, eventually proceeding to fibrosis of glomerular 
and tubulointerstitial compartments [78, 79]. Current evidence suggests an 
active role of H2S in the pathogenesis of DN. Plasma H2S level in DN patients 
is significantly lower than that in non-DN patients undergoing chronic 
hemodialysis [80]. High urinary sulfate concentration, a reflection of high 
plasma H2S level, is associated with reduced risk of renal disease progression 
in type 2 diabetes [81] and slower decline in Cr
51
-EDTA-assessed GFR in DN 
patients [82]. Recent data suggested that the renal expression of H2S 
producing enzyme CBS and CSE is down-regulated in pancreatic β-cell 
specific calmodulin-overexpressing transgenic (CaMTg) diabetic mice [32], 
C57BL/KsJ lepr
-/-
 db/db mice [83], streptozotocin-diabetic rats [84] and Akita 
diabetic mice [85]. Inhibition of CSE with PAG mimics high glucose-induced 
glomerular podocyte injury [86], implying a contributive role of endogenous 
H2S in DN. The mechanisms underlying CBS and CSE reduction have been 
also studied. Kundu et al. [85] showed that matrix metalloproteinase-9 (MMP-
9) was upregulated in Akita diabetic mice along with the reduction of CBS 
and CSE. When MMP-9 is knocked out, the expression of the two H2S 
producing enzyme namely CSE and CBS shows a trend toward baseline 
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despite hyperglycemia [85], suggesting that MMP-9 regulates CBS and CSE 
expression in DN.  
Meanwhile, exogenous H2S has been proved to be effective in in vitro and in 
vivo DN models. High glucose caused cell proliferation and collagen 
formation are attenuated by NaSH in cultured messangial cells [84] and 
tubular cells [87]. Moreover, NaSH alone [47, 83-90] or with losartan [91] 
ameliorates renal dysfunction and fibrosis formation in various DN related 
animal models.  
1.1.3.4.2 H2S in hypertensive nephropathy 
Hypertensive nephropathy is the second leading cause of chronic kidney 
disease worldwide [92]. Long time of high blood pressure load results in 
damages of kidney, especially in glomerulus. When kidney cannot function 
properly, it fails to regulate blood pressure. In turn, blood pressure will rise up 
which further aggravates renal damage [93].  Extensive evidence suggests a 
role of H2S in blood pressure control. Genetic deletion of CSE causes 
hypertension and diminished endothelium dependent vasorelaxation [94]. 
Similar with this, inhibition of both CBS and CSE also increases blood 
pressure in rat [39]. These data implies that H2S is a physiologic regulator of 
blood pressure. Further studies suggest that H2S functions as both an 
endothelium-derived hyperpolarizing factor [95-97] and an endothelium-
derived relaxing factor  [98]. The blood pressure lowering effect of exogenous 
H2S has been subsequently determined. Our group first showed that NaSH 
attenuated blood pressure by inhibiting plasma renin activity in a 2K1C rat 
model [45]. Thereafter, NaSH was demonstrated to reduce blood pressure in 
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spontaneous hypertensive rats [99], angiotensin II treated mice [100] and sFlt 
transgenic mice [101]. Additionally, renal protective effects of H2S have also 
been reported in hypertensive nephropathy. sFlt overexpression in mouse 
results in hypertension with proteinuria and glomerular endothelosis, all of 
which are apparently attenuated by administration of NaSH [101]. Further 
study suggests an involvement of vascular endothelial growth factor in this 
H2S mediated effect [101]. Recently, Jin’s group reported that both NaSH and 
its metabolite sodium thiosulfate attenuated angiotensin II induced proteinuria, 
renal dysfunction, and structural deterioration in rat [100]. Further studies 
suggested that the renal effects of H2S were partially mediated by suppression 
of epithelial sodium channel [102, 103].  
1.1.4 H2S in cancer biology and treatment 
Intriguingly, accumulative evidence indicates the involvement of H2S in 
cancer biology in recent years. In this section, the role of H2S is briefly 
reviewed in the context of cancer biology with an emphasis on H2S donation 
for cancer treatment. 
1.1.4.1 Dual role of H2S in cancer development 
The three H2S producing enzymes namely CSE, CBS and 3MST have been 
found highly expressed in numerous types of cancer [104]. Moreover, 
inhibition of H2S producing enzyme CBS has shown anti-tumor activity 
particularly in colon cancer, ovarian cancer and breast cancer [105, 106], 
whereas the consequence of CSE or 3MST inhibition remains largely 
unexplored in cancer cells. Intriguingly, H2S donation at high concentration 
has also been observed to induce cancer cell apoptosis while sparing 
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noncancerous fibroblast cells [107, 108]. Recently, Hellmich et al [109] 
proposed a reasonable bell-shaped model to illustrate the effects of H2S in 
cancer cells. In the model (Figure 1-3A), a bell-shaped curve is employed to 
describe the effects of H2S on cancer cell proliferation. In general, endogenous 
H2S or relatively low level of exogenous H2S exhibits pro-cancer effect. In 
contrast, exposure to H2S with high amounts leads to cancer cell death. This is 
consolidated by the fact that CBS inhibition not only leads to the inhibition of 
cell growth but also limits the toxic effect of either 3 mM NaSH or 3 mM 
GYY4137 in colon cancer line HCT116 [109]. Moreover, SAM, the allosteric 
CBS activator, promotes cancer cell proliferation at a lower concentration 
range (0.1-0.3 mM). However, it inhibits cell proliferation at a higher 
concentration range (1-3 mM) and this effect can be partially blocked by CBS 
silencing [109], suggesting that overactivation of H2S producing enzymes can 
also suppress cancer cell proliferation. In addition, continuous 
supplementation of NaSH, even at low concentration (5-20 µM; every 2 h), 
induces cancer cell death while sparing non-cancerous cells like MCF10A and 
WI-38 after 5 days [108]. This effect is well reflected with the slowly 
releasing H2S donor GYY4137 [108]. These results suggest that long time 
exposure to H2S, even at low doses, can also cause cancer cell death. 
Therefore, we herein propose another bell-shaped model to explain the time 
course effect of H2S on cancer cells (Figure 1-3B). Taken together, the bell 
shaped models may provide a valuable framework to harmonize seemingly 
controversial roles of H2S in cancer development. Meanwhile, it suggests that 





1.1.4.2 H2S donation for cancer treatment 
H2S donation especially at high doses or long time duration leads to cancer 
cell death without affecting the viability of normal fibroblast cells. The 
possible mechanisms underlying the detrimental effects of H2S are reviewed in 
the context of cancer development (Figure 1-4). 
1.1.4.2.1 H2S induces uncontrolled cellular acidification 
One hallmark of cancer cells is the utilization of glycolysis as the main 
pathway for energy production [110]. Thus, they tend to have enhanced 
capacity for glucose uptake and its conversion into lactate. Lactate 
accumulation results in cellular acidification and stress. However, cancer cells 
can efficiently export intracellular acid out of cells, which helps form an acidic 
 
Figure 1-3: The bell shaped models for the dual role of H2S in cancer 
development. (A) A bell-shaped curve is employed to describe the concentration 
dependent effect of H2S on cancer cell proliferation. In general, endogenous H2S or 
relatively low level of exogenous H2S exhibits pro-cancer effect. In contrast, 
exposure of H2S high amounts leads to cancer cell death. (B) A bell-shaped curve to 
explain the time dependent effect of H2S on cancer proliferation. Specifically, short 
time exposure of a low level of H2S may be beneficial for cancer cell growth, while 
long time exposure can cause cancer cell death. The models suggest that H2S 














microenvironment promoting angiogenesis and tumor metastasis [111]. 
Therefore, targeting regulators of intracellular pH is believed to be a 
promising strategy for cancer treatment [112]. It was found that an H2S slowly 
releasing donor GYY4137 (200-1000 µM) enhances glycolysis of cancer cells 
by increasing the uptake of glucose, meanwhile disrupting the exportation of 
intracellular acid possibly by suppressing the activity of anion exchanger (AE) 
and sodium/proton exchanger (NHE) [107]. As a result, this causes 
uncontrolled intracellular acidification and subsequent cell death in a panel of 
cancer cell lines [107]. ZYJ1122, the backbone molecule of GYY4137, has no 
such effect [107, 108], suggesting that the aforementioned activity of 
GYY4137 may be exclusively derived from H2S. Intriguingly, GYY4137 
exhibits strong anti-tumor effect in mice models [108]. The effect of 
GYY4137 has also been studied in fibroblast cells such as WI-38 and 
MCF10A in the study [107, 108]. The results showed that GYY4137 caused 
no changes on intracellular acidification and cell death in these non-cancerous 
cells, indicating its potential for cancer therapy. 
 
1.1.4.2.2 H2S suppresses cell survival signaling pathway 
Cancer cells disrupt the balance between apoptosis and survival through 
sustained activation of pro-survival signaling pathways, leading to the constant 
increase of cancer cell numbers [113]. NF-κb pathway acts as such a signaling 
pathway and its abnormal activation has been commonly found in various 
types of cancers including non-small lung cancer, breast cancer, prostate 
cancer et al [114]. H2S inhibits inflammatory response by suppression of 
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TNFα and LPS stimulated NF-κb activation [115, 116]. Therefore, it is not 
surprising to find that constant exposure of cancer cells to H2S [117] or its 
donating hybrids [118] suppresses NF-κb activity and causes cancer cell 
apoptosis. Additionally, other pro-survival signaling pathway may also 
account for the anti-cancer effect of H2S. For instance, GYY4137 causes the 
apoptosis of hepatocellular carcinoma cell lines by suppression of STAT3 
activation and down-regulation of STAT3 mediated downstream proteins such 
as Bcl-2, survivin and vascular endothelial growth factor [119]. In oral cancer 
cell lines, constant exposure of H2S gas causes cell apoptosis due to the 
inhibition of pleckstrin homology-like domain, family A, member 1, an 
apoptotic suppressor in these cell lines [120].  In the future, H2S targeted 
protein(s) in cell survival pathways need(s) to be unveiled and studied in 
details. 
1.1.4.2.3 H2S induces cell cycle arrest 
Dysregulation of cell cycle has been proven to be involved in cancer 
progression [121]. Thus, induction of cell cycle arrest is effective to treat 
cancer [122]. The suppressive effect of H2S on cell cycle transition has been 
suggested by numerous studies.  S-proargyl-cysteine (SPRC), a H2S donor, 
causes cell cycle arrest at G1/S phase in gastric cancer cell line SGC-7901 and 
subsequent apoptosis both in vitro and in vivo [123]. NaSH (0.4-1 mM) leads 
to cell cycle arrest at G1/S possibly by upregulating cyclin-dependent kinase 
inhibitor p21
Cip1
 in a panel of colon cancer cell lines (HT-29, SW116 and 
HCT116) [124]. The inductive effect of GYY4137 on cell cycle arrest has also 
been suggested in various cancer types [108, 119]. For instance, Wang’s group 
found that GYY4137 suppressed G1/S cell cycle transition by downregulating 
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the expression of cyclin D1 and the tumor growth was inhibited in the 
subcutaneous HepG2 xenograft model as a result [119]. Deng’s group reported 
that GYY4137 caused partial G2/M arrest in breast cancer cell line MCF7 
whereas the underlying mechanism was not studied [108]. Importantly, H2S 
seems to specifically induce cell cycle arrest in cancer cells as neither NaSH 
or GYY4137 causes cell cycle arrest in normal fibroblast cells in the 





Figure 1-4: Inhibitory effects of H2S in cancer development. (A) H2S induces 
uncontrolled cellular acidification. H2S stimulates the rate of glycolysis by 
enhancing the uptake of glucose which leads to the accumulation of lactate and 
intracellular acid. Due to the inhibitory effect of H2S on the activity of AE and 
NHE, the intracellular acid cannot be efficiently exported out of cells which cause 
cancer cell death. (B) H2S suppresses cell survival signaling pathway. H2S has been 
found to suppress the activity of cell survival pathways like NF-κb and STAT3 and 
therefore downregulates the downstream anti-apoptotic proteins which leads to 
cancer cell death. (C) H2S induces cell cycle arrest. H2S induces cell cycle arrest at 
G1/S by upregulating the expression of p21
Cip1 
and downregulating expression of 
cyclin D1. Besides, H2S was also found to induce cell cycle arrest at G2/M, 
however, the underlying mechanism has not been studied. GluT: glucose 




1.1.5 H2S donors 
Alongside the revelation of H2S as an endogenous signaling molecule, 
exogenous application of H2S has been suggested to elicit broad protective 
effect in cells derived from multiple organs. This makes H2S a promising 
therapy for human diseases which leads to the synthesis of various types of 
H2S donors. In this section, three commonly used H2S donors including NaSH, 
GYY4137 and AP39 are briefly reviewed. The molecular structure of these 






Figure 1-5: Structural components of H2S donors used in the study. (A) H2S acute 





1.1.5.1 H2S acute releaser NaSH  
NaSH is the most commonly used H2S donor in the field of H2S biology. It 
readily dissolves in physiological solution and forms HS
-
 and H2S [10]. As it 
does not have any backbone structures, it is believed that the biological effects 
derived from the molecule are solely from H2S. In the context of cancer 
biology, the effect of NaSH appears to be concentration dependent. 
Specifically, it promotes cancer cell proliferation at low doses and inhibits 
cancer cell growth at high concentration  [109]. Additionally, the 
concentration dependent effect of NaSH has also been observed in non-
cancerous cells such as heart cells and smooth muscle cells [125], indicating a 
possible marginal therapeutic index of the compound. Additionally, the other 
concern of utilizing NaSH is that it releases H2S at an uncontrolled manner 
and may cause acute toxicity to organs. Taken together, NaSH serves as a 
great tool compound to illustrate H2S mediated biological effects and the 
underlying mechanisms whereas the feasibility is rather low to translate it as a 
therapeutic drug. 
1.1.5.2 H2S slow releaser GYY4137 
GYY4137 is the first phosphinodithioate derived H2S releasing compound 
which was synthesized in 2008 [69]. It slowly releases H2S in aqueous 
solution and after intravenous or intraperitoneal injection in animals, closely 
mirroring the physiologically releasing manner of H2S from mammalian cells 
[69]. Therefore, it has been extensively used to study both physiological and 
therapeutic effects of H2S ever since its development. The anti-cancer effect of 
GYY4137 has also been demonstrated in vitro and in vivo [107, 108, 119]. 
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Importantly, GYY4137 induces cell apoptosis in cancer cell lines without 
affecting the cell viability of noncancerous fibroblast cells [107, 108], 
indicating the potential value of the molecule for cancer treatment.   
1.1.5.3 H2S mitochondrial releaser AP39 
AP39 is a H2S donor recently synthesized which specifically releases H2S in 
cellular mitochondria [67]. Thus, it is a great tool compound for studying the 
role of mitochondrial H2S in both physiological and pathological conditions. 
In recent years, AP39 has shown to be able to attenuate mitochondrial ROS 
generation and protected cells against ischemia and reperfusion injuries [67].  
In the current study, AP39 was used to explore whether supplying H2S into 
mitochondria can alleviate cisplatin induced RPT cell death. 
 
 
1.2 Polysulfide: a novel H2S derived signaling molecule 
Alongside the revelation of physiological roles of H2S, emerging evidence 
suggests that polysulfide may be a novel signaling molecule derived from H2S 
in recent years. Herein, recent advances on the biological roles of polysulfide 
are summarized below. Nonetheless, one should bear in mind that the field of 
polysulfide is still in its infancy and therefore a detailed portrayal of 
polysulfide in mammals still awaits to be drawn in the future. 
1.2.1 Structures and donors of polysulfide 
Polysulfide is a category of chemical compounds comprising chains of sulfur 
atoms. There are two main classes of polysulfide reported namely anions and 
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organic polysulfide [126]. Anions have the general formula Sn
2-
 which is the 
chemical basis of hydrogen polysulfide H2Sn and sodium polysulfide Na2Sn 
(Figure 1-6A). Organic polysulfide, such as garlic derived diallyl disulfides 
(DADS) and diallyl trisulfides (DATS), usually possess a formula of RSnR 
where R is either an alkyl or aryl group (Figure 1-6B). In the current study, we 
have employed sodium polysulfide Na2Sn as donors because they solely 
provide Sn
2- 
in aqueous solutions and therefore should be able to more closely 









1.2.2 Polysulfide generation in mammals 
Similar with H2S, polysulfide is suggested to be produced in mammals 
through both non-enzymatic pathway and enzymatic pathway. However, the 
portion of endogenous polysulfide generated by these pathways remains 
elusive. Besides, the regulation of polysulfide production is also not well 
understood. 
 
Figure 1-6: Structural components of polysulfide donors. (A) Anionic polysulfide 
donors including Na2S2, Na2S3 and Na2S4. These donors were employed in the 
current study. (B) Organic polysulfide donors including DADS and DATS. DADS: 
diallyl disulfides; DATS: diallyl trisulfides. 
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1.2.2.1 Non-enzymatic generation of polysulfide 
In the presence of oxygen, polysulfide is generated from H2S as described in 
the following equation: 2nH2S + 1/2 (2n-1)O2     H2S2n + (2n-1)H2S [127]. 
Nevertheless, the reaction shown here with 02 is very slow unless it is 
catalyzed by a transition metal and this may not occur that much inside of the 
cell. Moreover, HS
-
 is also able to react with sulfur S
0
 to generate polysulfide 
containing various numbers of sulfurs [128]. When the number of sulfur 
reaches 8, the sulfur molecule cyclizes and becomes stable. Recently, another 
reaction was identified in which polysulfide serves as a product of the 
interaction between H2S and NO [129].  Importantly, these reactions should be 
partially responsible for the production of polysulfide in mammalian systems 
as they can occur at physiological conditions  [129]. 
1.2.2.2 Enzymatic generation of polysulfide 
Intriguingly, Kimura and others [130] found that hydrogen polysulfide H2Sn 
can be also produced by enzymatic reaction catalyzed by H2S producing 
enzyme 3MST. In the study, they found that 3MP promoted the production of 
H2Sn in brain cells of wide-type mice but not 3MST deficient mice, suggesting 
that H2Sn may be exclusively produced by 3MST. Moreover, purified 
recombinant 3MST also facilitates the production of H2Sn in the presence of 
3MP. However, mutation of the cysteine residue at the catalytic site of 3MST 
leads to the failure in producing H2S and H2Sn. Additionally, H2S can be used 
as a direct substrate for the production of H2Sn by 3MST in the cooperation of 
rhodanese [130]. It is believed that polysulfide can also be generated by these 
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pathways in other mammalian systems due to the universal presence of 3MST 
[131].  
1.2.3 Biological roles of polysulfide in mammals 
Although the biological functions of polysulfide are not fully acknowledged, 
current evidence tends to show that polysulfide may possess similar function 
with H2S yet with higher potency. Herein, the possible biological functions of 
polysulfide are summarized, including regulation of intracellular Ca
2+
, cellular 
protective effects and anti-cancer activity. 
1.2.3.1 Polysulfide regulates intracellular Ca
2+
 
Nagai et al. [132] found that polysulfide was able to activate TRPV channels 
more potently than H2S. Subsequently, Oosumi and others [133] determined 
that Cysteine 422 and Cysteine 622 in the TRPV 1 channel were sensitive to 
polysulfide.  Additionally, the modification of NMDA receptor by polysulfide 
was also reported by Kimura’s group [134], which facilitates the induction of 
long term potential in neurons.  
1.2.3.2 Polysulfide elicits cellular protective effect  
Intriguingly, polysulfide was also found to elicit cytoprotective effect by 
multiple mechanisms. For instance, Koike and colleagues [135] initially 
reported that polysulfide exhibited protective effects against cytotoxicity 
caused by oxidative stress in neuronal cell SH-SY5Y. Thereafter, they showed 
that polysulfide may induce the translocation of Nrf2 into nucleus by 
dimerization of Keap1. As a result, Nrf2 regulated anti-oxidant genes are 
expressed which afford protective effect in cells  [135]. Additionally, 
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polysulfide also induces the activation of AKT pathway which may also be 
involved in its cell protective effect [136].  
1.2.3.3 Garlic derived polysulfide possesses anti-cancer activity 
Garlic has been extensively used for numerous diseases in traditional Chinese 
medicine [137]. It is abundant with sulfur-containing compounds which can be 
easily recognized with a smell. Among these compounds, allicin has been 
extracted and studied thoroughly. Intriguingly, compiling evidence suggests 
that allicin possesses anti-cancer effects in various types of cancer in vitro and 
in vivo [138-140]. Allicin is very unstable and discomposes quickly into 
organic polysulfides including DADS and DATS. Therefore, these individual 
compounds have also been synthesized and tested in cancer models. The 
results showed that both the compounds exhibited strong anti-cancer activity 
in in vitro and in vivo models [141]. 
1.3 Cisplatin nephrotoxicity 
Cisplatin is a simple compound, only containing a central platinum atom 
surrounded by two chlorine atoms and two ammonia groups in a cis 
configuration. Nevertheless, it is an extremely effective chemotherapeutic 
drug for cancer treatment. For example, it is widely used for the treatment of 
many solid tumors from organs such as head, neck, lung, testis, ovary, and 
breast [142]. However, its usage in cancer therapy is largely compromised due 
to numerous adverse effects including nephrotoxicity, hearing loss, 
neurotoxicity, severe nausea and myelosuppression [143]. Among these 
adverse effects, nephrotoxicity is the most prevalent one as evidence shows 
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that over 30% of patients show symptoms of AKI following the administration 
of cisplatin [144].  
1.3.1 Clinical features of cisplatin nephrotoxicity 
Cisplatin nephrotoxicity was initially described in clinical trials of cisplatin for 
cancer therapy [145], followed by a similar observation in a number of species 
such as mice, rats and dogs [146]. Typically, renal insufficiency begins as 
manifested by increases of serum creatinine and blood urea nitrogen levels 
several days after the administration of cisplatin, along with a reduction of 
serum magnesium and potassium levels [147]. Meanwhile, the urine output is 
normally preserved and it usually contains glucose and small amounts of 
protein, indicating the dysfunction of proximal tubule [147]. Recovery of renal 
function usually occurs over a period of 2-4 weeks provided the 
discontinuation of cisplatin administration; however, progressive and 
permanent nephrotoxicity may appear even with preventive measures [148, 
149].  
1.3.2 Risk factors of cisplatin nephrotoxicity 
Several risk factors have been identified to be associated with cisplatin 
nephrotoxicity. Accumulative evidence suggests that cumulative and/or high 
dose of cisplatin increase the rate of nephrotoxicity [150, 151]. Besides this, 
other factors such as smoking, older age, female sex and pre-existing renal 
dysfunction are also found to associate with increased incidences of 
nephrotoxicity [152, 153]. However, whether pre-existence of chronic kidney 
diseases influences the occurrence of cisplatin nephrotoxicity remains elusive 
due to limited data reported. In contrast, diabetes was reported to lower the 
risk of cisplatin nephrotoxicity in rats [154]; however, such effect was not 
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observed in human clinical trials [155, 156]. Moreover, certain mutations in 
the gene of organic cation transporter 2 (OCT2) may associate with a lower 
risk of nephrotoxicity, probably because OCT2 regulates the transportation of 
platinum into kidney cells [157, 158]. 
1.3.3 Disease pathophysiology of cisplatin nephrotoxicity 
After decades of studies, the pathophysiology underlying cisplatin 
nephrotoxicity is gradually disclosed. In this section, the possible signaling 
and molecular mechanisms underlying the disease pathophysiology are 
summarized and illustrated in Figure 1-7. 
 
 
Figure 1-7: Disease pathophysiology of cisplatin nephrotoxicity. When passing 
through renal tubules, cisplatin is actively accumulated into RPT cells due to the 
abundance of OCT2 on the cell membrane of RPT cells. This leads to the massive 
production of intracellular ROS and inflammatory responses, both of which contribute 
to RPT cells death and following acute kidney injury. RPT: renal proximal tubule; 





1.3.3.1 Accumulation of cisplatin in kidney cells 
The clearance of cisplatin in mammals mainly occurs in kidney by both 
glomerular filtration and tubular secretion [159]. In line with this, the 
concentration of cisplatin in kidney largely exceeds its concentration in plasma, 
indicating an accumulation of the drug in renal cells [159]. This has been 
demonstrated with kidney slices and cultured renal proximal tubule segments 
[160, 161]. In recent years, two different transporters namely copper 
transporter 1 (Ctr1) and organic cation transporter 2 (OCT2) have been 
identified responsible for the active transportation of cisplatin into mammalian 
cells. Ctr1 is highly expressed both in adult kidney and mammalian cells such 
as ovarian cancer cells [162]. Downregulation of Ctr1 in kidney cells 
attenuates cisplatin accumulation and subsequent toxicity [163], indicating 
that Ctr1 at least partially mediates the accumulation of cisplatin into kidney 
cells. However, whether Ctrl takes part in cisplain nephrotoxicity in vivo has 
not been studied. Unlike the universal expression of Ctr1, OCT2 is mainly 
located in renal proximal tubule cells [164]. Initially, it was found that 
cisplatin suppressed the transport of other OCT2 substrates into renal cells 
[164]. Conversely, an OCT2 substrate cimetidine decreases the uptake of 
cisplatin and cytotoxicity in vitro [165] and nephrotoxicity in animals [158], 
suggesting a role of OCT2 in cisplatin nephrotoxicity. This notion is strongly 
supported by a recent study which showed that OCT2 knockout mice 
exhibited higher resistance to cisplatin nephrotoxicity and lower urinary 
cisplatin excretion [157, 158]. Consistently, certain mutations of OCT2 gene 
are associated with reduced risk of cisplatin nephrotoxicity in patients [157].  
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1.3.3.2 Cell death in cisplatin nephrotoxicity: types and location 
Cisplatin nephrotoxicity is characterized with massive tubular cell death, 
consisting of both necrosis and apoptosis [166]. Recent studies have suggested 
that dosage of cisplatin may determine whether cells undergo necrosis or 
apoptosis [167]. For example, milimolar concentration of cisplatin causes 
tubular cell necrosis in hours, while lower concentration of cisplatin 
(micromolar) leads to apoptosis in cultured tubular cells [167]. Nevertheless, it 
is also likely that necrosis may be a postmortem result of apoptosis, termed 
secondary necrosis. It has been well recognized that renal tubules are the 
major sites of cell death during cisplatin nephrotoxicity; however, it is not 
until recently that the type of cells injured by cisplatin was identified. By using 
proximal and distal tubule-specific lectins, it was observed that most of 
apoptotic cells can be stained with a proximal tubule-binding lectin namely 
phytohemagglutinin while only very small portion of apoptotic cells were 
stained by peanut lectin agglutinin which specifically stains distal tubule [168]. 
This result indicates that cisplatin mainly causes proximal tubule cell death 
which may lead to subsequent renal dysfunction. Therefore, a well-established 
renal proximal tubule (RPT) cell line LLC-PK1was used for the whole in vitro 
studies.  
1.3.3.3 Oxidative stress in cisplatin nephrotoxicity 
Oxidative stress has long been recognized as an important factor contributing 
to cisplatin nephrotoxicity [169]. Numerous studies have observed the massive 
production of ROS upon cisplatin treatment in cultured renal tubular cells, 
kidney slices, and in vivo animals [170, 171]. Further studies have suggested 
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three possible mechanisms accounting for the generation of ROS. First, 
cisplatin may cause mitochondrial ROS generation by suppressing 
mitochondrial respiratory chain. For example, the activity of complex I-IV is 
reduced by 15-55% in 20 min after cisplatin treatment in tubule cells which 
may result in ROS production [172]. However, one should bear in mind that 
ROS generation under this situation actually relies on residual electron flow 
through mitochondrial respiratory chain; and therefore inhibition of the 
respiratory chain may block ROS accumulation [172]. Second, cisplatin may 
result in ROS production by activating the activity of NADPH oxidase. In 
agreement with this, pharmacological inhibition of NADPH oxidase protects 
renal cells in cultured proximal tubule cells and in vivo animals [173-175]. 
Finally, cisplatin may lead to ROS formation in the microsomes via the 
cytochrome P450 (CYP) system. This is supported by evidence that knockout 
of CYP2E1 not only attenuates ROS accumulation but also alleviates cisplatin 
caused renal injury [176]. In line with these findings, numerous anti-oxidants 
have been extensively studied in cisplatin nephrotoxicity and some of them are 
undergoing clinical trials [177].  
1.3.3.4 MAPK activation in cisplatin nephrotoxicity 
The MAPK (mitogen-activated protein kinase)-signaling pathways consist of 
ERK, p38 and JNK pathway. The activation of MAPKs plays critical roles in 
the regulation of proliferation, differentiation and apoptosis [178]. Emerging 
evidence suggests the activation of MAPKs in various experimental models of 
cisplatin nephrotoxicity. For example, Nowak et al first described that the 
activation of ERK led to its accumulation in mitochondria upon cisplatin 
treatment in primary renal tubule cells [179]. Pharmacological inhibition of 
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ERK by PD98059 or U0126 largely ameliorates cisplatin caused apoptosis 
[180]. In line with this, overexpression of constitutively active MEK1 leads to 
enhanced apoptosis, while dominant negative MEK1 decreases cisplatin 
induced apoptosis in renal tubular cells. Importantly, ERK inhibitor U0126 
attenuates in vivo cisplatin nephrotoxicity [181], suggesting its involvement in 
cisplatin caused renal toxicity.  Similarly, p38 and JNK were also reported to 
be activated upon cisplatin treatment in animals [180]. Inhibiting either of the 
two kinases was reported to be protective in cisplatin induced nephrotoxicity 
[182, 183]. Besides, p38 may also take part in the regulation of TNFα 
expression and following inflammatory response during cisplatin 
nephrotoxicity [182, 183].  
1.3.3.5 Inflammation in cisplatin nephrotoxicity 
Cisplatin induced kidney injury is associated with apparent inflammatory 
responses [184]. Massive expression of cytokines such as TNFα, IL-2 and 
MCP-1 has been reported in cisplatin treated kidneys [185]. Deng et al firstly 
showed that IL-10 can attenuate cisplatin induced renal tissue injury and 
tubular apoptosis, suggesting inflammatory response contributes to cisplatin 
nephrotoxicity [185]. Recent studies suggest that TNFα appears to be the key 
regulator of inflammatory response induced by cisplatin [185-187]. For 
example, TNFR2-deficient mice show higher resistance to cisplatin induced 
nephrotoxicity compared with that of control [186]. Moreover, Reeves and 
others showed that TNFα was crucial for the recruitment of inflammatory cells 
and upregulation of other pro-inflammatory factors because blockage of TNFα 
largely diminished above mentioned effects [187]. Recently, the initial 
production of TNFα during cisplatin nephrotoxicity was ascribed to proximal 
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tubular cells instead of infiltrated inflammatory cells [188]. This further 
demonstrates the pivotal role of renal RPT cell in the pathogenesis of cisplatin 
nephrotoxicity. Importantly, Faubel and colleagues showed that IL-1b, IL-18, 
and IL-6 may not significantly contribute to cisplatin induced renal toxicity 
[189]. However, the involvement of other cytokines remains to be determined. 
1.3.4 Prevention of cisplatin nephrotoxicity 
Volume expansion by hydration has shown some success in the prevention of 
cisplatin nephrotoxicity [190]. However, the use of these diuretics such as 
mannitol or furosemide fails to provide any beneficial effects in the scenario 
of cisplatin nephrotoxicity in spite of their inclusion in many hydration 
regimens [191]. In fact, one comparative study observed aggravated 
nephrotoxicity in patients received mannitol plus saline in comparison to those 
that received saline alone [192]. As a result, a recently issued clinical 
guideline suggests volume expansion with 0.9% saline and avoidance of 
diuretics [193].  
Another approach aiming to prevent cisplatin nephrotoxicity is to synthesize 
and screen novel analogues of cisplatin with lower toxicity to normal cells. In 
this direction, carboplatin, an analogue of cisplatin has been approved for 
clinical usage of multiple cancers [194]. Compared with cisplatin, carboplatin 
shows less risk of toxicity for gastrointestinal, renal and neurologic effects 
[194]; however, carboplatin appears to be less potent in terms of therapeutic 
effectiveness at least in cancers containing germ cell tumors, bladder cancer, 
head and neck cancer according to a clinical study [195].  
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1.4 Research rational and objectives 
1.4.1 Research rational 
Due to the remarkable ability to treat various forms of cancers, cisplatin has 
gained the reputation as ‘the penicillin of cancer’ [196]. However, its effective 
usage for cancer therapy has been largely limited because of numerous 
adverse effects [143]. Among these adverse effects,  nephrotoxicity is the most 
prevalent one as evidence shows that over 30% of patients show symptoms of 
acute kidney injury following the administration of cisplatin [144]. However, 
effective therapy for this devastating disease remains lacking. Therefore, more 
studies are warranted to better understand the pathogenesis of cisplatin 
nephrotoxicity and discover novel strategies for its prevention and treatment.  
H2S, an endogenous signaling molecule, has been shown to participate in the 
regulation of both renal physiology and diseases. In physiological conditions, 
it is able to regulate the excretory function of kidney [37]. Likewise, it can 
reduce blood pressure by attenuating renin release [45]. Afterwards, reduction 
of endogenous H2S was found to involve in various kidney diseases including 
renal ischemia/reperfusion [59, 60], obstructive nephropathy [73], diabetic 
nephropathy  [32] and hypertensive nephropathy [99]. The renal mRNA levels 
of CSE and CBS was found to be decreased in mice upon cisplatin treatment 
[197]; however, whether endogenous H2S is involved in the disease 
progression remains elusive. Therefore, it is intriguing to define the role of 
endogenous H2S in cisplatin nephrotoxicity. 
Alongside the revelation of H2S as an endogenous signaling molecule, 
exogenous application of H2S has been suggested to elicit broad protective 
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effect in cells derived from multiple organs. This makes H2S a promising 
therapy for human diseases which leads to synthesis of various types of H2S 
donors such as slow releaser GYY4137 [69]  and mitochondrial releaser AP39 
[198]. In renal system, H2S donors protects renal cells and renal function in 
above mentioned pathological conditions [199]. Further studies have 
suggested that the protective effects of H2S can be attributed to its anti-oxidant, 
anti-inflammatory and anti-apoptotic capabilities [35, 67, 76, 200, 201]. 
Importantly, H2S exhibits both cell protective effects and anti-cancer effects. 
Interestingly, at doses that apparently inhibit cancer cell growth H2S affords 
beneficial effects in normal cells against cellular stresses such oxidative stress 
and inflammation which is clearly indicated by using H2S slowing releasing 
compound GYY4137 [202-206]. Therefore, it is hypothesized that H2S 
donation may be a promising strategy for the treatment of cisplatin 
nephrotoxicity which is mainly caused by oxidative stress and inflammation 
[170, 177]. By this strategy, it is speculated that H2S donation may alleviate 
cisplatin caused renal toxicity without affecting its anti-cancer activity.   
In recent years, emerging evidence has suggested that polysulfide may be a 
novel signaling molecules alongside H2S. Intriguingly, it is not only directly 
derived from H2S, but also generated by H2S producing enzyme 3MST [207]. 
Although the biological functions of polysulfide are not fully acknowledged, 
current evidence tends to show that polysulfide may possess similar function 
with H2S yet with higher potency. Therefore, it is of great value to examine 





The main objectives of the thesis were to investigate the role and therapeutic 
potential of H2S and polysulfide in cisplatin nephrotoxicity in both in vitro and 
in vivo models. Specifically, this study sought to examine: 
 The alternation and the possible involvement of endogenous H2S in the 
pathogenesis of cisplatin nephrotoxicity; 
 The therapeutic value and underlying mechanisms of various H2S 
donors (NaSH, GYY4137 and AP39) in the treatment of cisplatin 
nephrotoxicity; and 
 The therapeutic value and underlying mechanisms of polysulfide in the 
treatment of cisplatin nephrotoxicity. 
The completion of the study should not only provide us an in-depth 
understanding of the pathogenesis, but also shed light on the discovery of 













Chapter II Involvement of endogenous H2S in cisplatin nephrotoxicity 
 
2.1 Introduction 
H2S has gained recognition as an endogenous gaseous transmitter alongside 
NO and CO. It is produced redundantly by four pathways in kidney, indicating 
the abundance of the molecule in the organ. In recent years, H2S has been 
shown to participate in the regulation of both renal physiology and diseases. In 
physiological conditions, it is able to suppress the activity of sodium 
transporters on renal tubular cells and thereby enhances the excretory function 
of kidney [37]. Likewise, it can reduce blood pressure by attenuating renin 
release caused by renin-angiotensin system overactivation [45]. Afterwards, 
reduction of endogenous H2S level has been observed in various kidney 
diseases including renal IRI [59, 60], obstructive nephropathy [73], diabetic 
nephropathy  [32] and hypertensive nephropathy [99]. Moreover, H2S 
reduction may contribute to the progression of the diseases as H2S 
supplementation with H2S donors protects renal cells and renal function in 
these pathological conditions [199].  
The role of H2S in cisplatin nephrotoxicity has not been determined, in spite of 
evidence showing the alternation of H2S producing enzymes in kidneys of 
cisplatin treated animals. For instance, Liu et al. recently showed that the 
mRNA levels of both CSE and CBS were severely decreased upon cisplatin 
treatment in mouse after 3 days [197]. Nevertheless, whether the alternation of 
the enzymes is implicated in the pathological process of the disease remains 
unknown. In the study, the changes of CBS and CSE expression in the region 
of renal cortex and in RPT cells were measured upon cisplatin treatment. 
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Moreover, their possible involvement in the disease progression was 
investigated within RPT cells. 
 
2.2 Materials and methods 
All experimental protocols mentioned in this and the rest of the chapters were 
approved by the Institutional Animal Care and Use Committee of the National 
University of Singapore. 
2.2.1Animal models 
Twelve male SD rats (200-220 g) were employed in the study.  The rats were 
equally divided into three groups. 8 rats were treated with 7 mg/kg cisplatin (1 
mg/ml in sterile saline solution) by a single intraperitoneal (i.p.) injection. 
Among them, 4 rats injected with cisplatin were sacrificed at day 3 while the 
remaining rats were sacrificed at day 6 after cisplatin administration. 4 rats 
treated with saline solution were served as controls. Blood and kidney were 
collected and stored in -80 °C when the animals were sacrificed. 
2.2.2 Measurement of plasma creatinine and blood urea nitrogen  
The levels of plasma creatinine and blood urea nitrogen (BUN) were measured 
using commercial kits from Bioassay System (DICT-500 & DIUR-100). 
Briefly, plasma (30 µL) was incubated with the reagent for 10 min and then 
the absorbance was detected at 510 nm for the measurement of plasma 
creatinine. For BUN measurement, plasma (10 µL) was used to react with the 
detection reagent for 30 min and the signal was read at 520 nm. 
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2.2.3 Measurement of H2S level in plasma 
The plasma level of H2S was measured with H2S probe 7-azido-4-
methylcoumarin (AzMC) as described previously [208]. Briefly, plasma (20 
µL) was collected after centrifuging and incubated with AzMC for 30 min at 
37 °C, and then fluorescence was measured with Varioskan Flash microplate 
reader (Waltham, MA. USA). 
2.2.4 Measurement of H2S synthesis activity 
H2S synthesis activity was measured as described previously [209]. Briefly, 
snap-frozen 100 mg of rat renal cortical tissue were homogenized in 1 ml of 
100 mM potassium phosphate buffer (pH 7.4). The assay mixture was made of 
10 mM L-cysteine, 2 mM pyridoxal 5’-phosphate and 460 µL tissue 
homogenate, which was incubated at 37 °C for 30 min. Subsequently, 250 µL 
of zinc acetate (1% wt/vol) was added to trap the generated H2S. The reaction 
was then stopped by 250 µL of trichloroacetic acid (10% wt/vol). 133 µL of N, 
N-dimethyl-p-phenylenediamine sulfate (20 mM) and 133 µL of FeCl3 (30 
mM) were added and centrifuged under 14,000 g for 5 min. The absorbance of 
200 µL respective supernatant was measured at 670 nm. The protein 
concentration was determined with BCA colorimetric protein kit. 
2.2.5 Cell culture 
The porcine RPT cell line namely LLC-PK1 was purchased from ATCC 
(Rockville, MA. USA) and cultured in DMEM supplemented with 10% (v/v) 
heat-inactivated fetal bovine serum (FBS), 1% penicillin (100 U)/streptomycin 
(100 mg/mL) in a humidified atmosphere of 95% air and 5% CO2 at 37 ℃. 




2.2.6 Hoechst 33342/propidium iodide staining 
Hoechst 33342/propidium iodide (PI) staining was performed in 96 well plates. 
After treatment, the cells were incubated with phenol red free DMEM 
containing with 5 µg/mL Hoechst 33342 and 15 µg/mL PI for 15 min at 37 °C. 
The images were taken in Cytation 3 imaging reader (BioTek, VT. USA).  
2.2.7 Cell viability assay 
The cell viability was tested by CCK-8 assay in 96 well plates with a 
commercial kit from Dojindo (Kumamoto, Japan). Shortly, 10 µL of CCK-8 
solution was added into each well containing 100 µL medium and treated cells. 
After incubating for 2 h, the absorbance was detected at 450 nm with a 
Varioskan Flash microplate reader (Waltham, MA. USA).  
2.2.8 Lactate dehydrogenase assay 
Lactate dehydrogenase (LDH) assay was performed with a commercial kit 
from Sigma-Aldrich (St Louis, MO. USA) according to the manufacturer’s 
instruction. Briefly, 50 µL medium after treatment was mixed with LDH 
detection reagents. After incubation, the absorbance was measured at 450 nm. 
2.2.9 Western blot assay 
Renal cortical tissue and cell samples were lysed with RIPA buffer containing 
phosphatase and protease inhibitors. The protein content was measured using 
BCA colorimetric protein kit. Equal amount of protein were separated with 12% 
SDS-PAGE and transferred onto a PVDF membrane. After blocking with 10% 
nonfat milk, the membranes were incubated with primary antibody overnight 
with mild shake at 4 °C.  Then the membrane was washed for 3 times with 
TBST buffer followed by 1 h incubation with horseradish peroxidase-
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conjugated secondary antibody. The immunoblots was visualized with ECL 
Western blotting substrate. Protein bands were normalized with non-
phosphorylated form of proteins or β-actin. 
2.2.10 Establishment of CSE overexpressing LLC-PK1 cells 
LLC-PK1 cells were cultured in 35 mm dish. Cells were transfected with 
mammalian expression vector pIRES2-EGFP containing CSE (CSE-pIRES2-
EGFP; a gift from Dr. Rui Wang). The cloning of CSE-pIRES2-EGFP was 
shown in the previous publication [210]. After 48 h of transfection, the cells 
were underwent antibiotic selection (800 µg/ml G418) for 5 weeks before 
using for experiments. 
2.2.11 Statistic analysis 
All results were expressed as the mean ± standard error of the mean (SEM). 
Statistical analysis was performed using one-way analysis of variance 











2.3.1 Cisplatin reduces plasma level of H2S in rat alongside renal 
dysfunction 
The effects of cisplatin treatment on renal function and H2S level in plasma 
were first examined.  As indicated in Figure 2-1A & 2B, renal dysfunction 
gradually appeared as manifested by the increased levels of blood creatinine 
and BUN at day 3 and day 6 upon cisplatin treatment. Thereafter, the H2S 
level in the plasma was examined with a H2S specific probe AzMC as 
described previously [208]. The results showed that cisplatin administration 
led to over 20% and 40% reduction of H2S level in plasma at day 3 and day 6 













Figure 2-1: Cisplatin reduced the plasma level of H2S in rat alongside kidney 
dysfunction. The plasma levels of creatinine (A), BUN (B), and H2S (C) upon 










2.3.2 Cisplatin impairs H2S generation and CSE expression in renal 
cortex 
The H2S generating capacity was further examined in the renal cortex which is 
the main residence for RPT cells. The results showed that the H2S generation 
capacity was significantly suppressed as early as day 3 in the region (Figure 2-
2A).  Thereafter, the protein levels of the two major H2S producing enzymes 
(i.e. CSE and CBS) were further examined.  As shown in Figure 2-2B &2C, 
the level of CSE was obviously downregulated while that of CBS was not 
apparently affected. Taken together, the results suggest that cisplatin causes 
Figure 2-2: Cisplatin impaired H2S generation and CSE expression in renal 
cortex. (A) The H2S production capacity upon cisplatin treatment in renal cortical 
tissues. (B-C) Expression levels of CBS and CSE upon cisplatin treatment in renal 










the reduction of endogenous H2S level in renal cortex which may be attributed 
to the downregulated expression of CSE. 
2.3.3 Cisplatin downregulates CSE expression prior to cell death in RPT 
cells 
As RPT cell death causes cisplatin nephrotoxicity, the possible role of 
endogenous H2S in the pathological process was therefore examined within 
RPT cells. The results showed that cisplatin treatment lessened CSE 
expression as early as 6 h (Figure 2-3A &3B) when the cell viability of RPT 
cells remained unaffected (Figure 2-3D). Similar with the results obtained in 
 
Figure 2-3: Cisplatin downregulated CSE expression prior to cell death in RPT 
cells. (A-C) Expression levels of CBS and CSE in RPT cells at various time points 
upon cisplatin treatment (30 µM). (D) Cell viability of RPT cells at various time points 






p<0.001 versus time 0 group.  
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the animal studies, no obvious change on the expression of CBS was observed 
(Figure 2-3A &3C). 
2.3.4 Overexpression of CSE attenuates cisplatin induced RPT cell death 
To investigate whether the downregulation of CSE is involved in cisplatin 
induced RPT cell death, a stable cell line was established to constitutively 
overexpress CSE (Figure 2-4A). As shown in Figure 2-4B, constant 
overexpression of CSE afforded RPT cells higher resistance against cell 
damages caused by cisplatin at various concentrations. This result suggests 






Figure 2-4: Overexpression of CSE attenuated cisplatin induced RPT cell death. 
(A) Western blots showing the expression level of CSE in WT and CSE 
overexpressing cells. (B) Comparison between LLC-PK1 and its CSE overexpressing 








2.3.5 H2S producing substrates alleviate cisplatin induced RPT cell death 
The effect of H2S producing substrates on cisplatin induced RPT cell death 
was further detected. As indicated in Figure 2-5A, the substrates apparently 
reduced cisplatin caused LDH release in a concentration dependent manner. 
Moreover, the protective effect was further consolidated with Hoechst/PI 
staining in which one can observe that H2S producing substrates almost 
completely abolished cisplatin induced PI positive cells (Figure 2-5B & 5C). 
These results indicate a protective effect of H2S producing substrates in 
cisplatin induced RPT cell death. 
 
Figure 2-5: H2S producing substrates alleviated cisplatin induced RPT cell death. 
(A) Effect of H2S producing substrates (pretreatment for 30 min) on cisplatin (30 µM, 
24 h) induced reduction of RPT cell viability. (B-C) Effect of H2S producing substrates 
(1 mM Cys and 0.1 mM Hcy, pretreatment for 30 min) on cisplatin (30 µM, 24 h) 
induced RPT cell death by Hoechst/PI staining. 
***









Endogenous H2S has been implicated in various kidney diseases [32, 59, 60, 
73, 99]; however, its role in cisplatin nephrotoxicity is not well defined. Using 
both in vitro and in vivo models, here the current study showed compelling 
evidence that cisplatin resulted in the reduction of endogenous H2S generation 
through downregulating the expression of CSE. However, the study failed to 
observe any obvious changes of CBS in both RPT cell and renal cortical 
tissues, indicating that cisplatin may influence the generation of endogenous 
H2S exclusively by downregulating CSE. Intriguingly, Liu et al. recently 
showed that the mRNA level of CSE was severely downregulated upon 
cisplatin treatment at day 3 in mouse kidney [76]. This suggests that cisplatin 
induced reduction of CSE and H2S level may be universal in the renal cortex 
in various mammalian species. In the future, the mechanisms underlying 
cisplatin mediated CSE downregulation need to be investigated. 
The fact of endogenous H2S reduction urged to study whether the gaseous 
transmitter is involved in the pathological process of the disease. To facilitate 
the study, LLC-PK1, a RPT cell line, was employed to examine the role of 
endogenous H2S, because it is known that RPT cell death leads to the 
following cisplatin nephrotoxicity [167]. Intriguingly, it was found that the 
reduction of CSE occurred prior to cell damage, implying the possible 
involvement of endogenous H2S in cisplatin induced RPT cell injury. This 
speculation was thereafter consolidated with several evidences. When CSE 
was constantly overexpressed, RPT cells tended to have higher resistance to 
cisplatin compared with wildtype cells. This suggests that endogenous H2S 
may protect RPT cell against cisplatin caused cell death. Following this, the 
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production of endogenous H2S was boosted by supplementing H2S producing 
substrates like L-cysteine and homocysteine. Remarkably, the data showed 
that the addition of these substances significantly attenuated cisplatin induced 
toxicity in RPT cells. Taken together, these results demonstrate the protective 
effect of endogenous H2S against cisplatin cause RPT cell injury and possibly 
renal damage. This implies that the reduction of CSE and endogenous H2S 
level may contribute to cisplatin nephrotoxicity. Nevertheless, H2S producing 
substrates may also lead to the increase of glutathione level in RPT cells 
which may also provide protective effect against cisplatin toxicity. To 
consolidate this conclusion, further studies may be required such as examining 
whether CSE deficiency worsens cisplatin nephrotoxicity in animals. 
Moreover, how the reduction of endogenous H2S influences the disease 
progression may also need to be explored in the future. 
Taken together, the results in the present study demonstrate the protective 
effect of endogenous H2S against cisplatin cause RPT cell injury and possibly 
renal damage. This implies that the reduction of CSE and endogenous H2S 
level may contribute to cisplatin nephrotoxicity. Moreover, this also suggests 
that supplementation of exogenous H2S may afford protective effect against 







Chapter III Renal protective effects of exogenous H2S in cisplatin 
nephrotoxicity 
 
3.1 Introduction  
Alongside the revelation of H2S as an endogenous signaling molecule, 
exogenous application of H2S has been suggested to elicit broad protective 
effect in cells derived from multiple organs. This makes H2S a promising 
therapy for human diseases which leads to synthesis of various types of H2S 
donors such as slow releaser GYY4137 [69] and mitochondrial releaser AP39 
[198]. In renal system, H2S donors protects renal cells and renal function in 
various pathological conditions such as renal IRI [59, 60], obstructive 
nephropathy [73], diabetic nephropathy [32] and hypertensive nephropathy 
[99]. Further studies have suggested that the protective effects of H2S can be 
attributed to its anti-oxidant, anti-inflammatory and anti-apoptotic capabilities 
[35, 67, 76, 200, 201].  
The results in the previous chapter indicate that reduction of endogenous H2S 
may contribute the pathogenesis of cisplatin induced RPT cell death and 
thereby nephrotoxicity. Therefore, it was hypothesized that H2S donation may 
be a promising strategy for the treatment of cisplatin nephrotoxicity.  
In the current chapter, several H2S donors namely NaSH, GYY4137 and AP39 
were studied in parallel to clarify the effect of exogenous H2S on cisplatin 
nephrotoxicity and to unclose the underlying mechanisms. Moreover, the 
effect of H2S donors on the anti-cancer activity of cisplatin was also examined 
with different cancer cell lines.  
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3.2 Materials and methods 
3.2.1 Cell culture  
Please refer to section 2.2.5. 
3.2.2 Cell viability assay 
Please refer to section 2.2.7. 
3.2.3 Intracellular ROS measurement 
The intracellular ROS was measured with a fluorescence dye CM-H2DCFDA 
in 96-well plate (Thermofisher, USA). After treatment, cells were washed with 
PBS and then incubated with 100 uL of DCFH-DA (10 µM, dissolved in 
phenol red-free DMEM) for 30 min at 37 ℃. The fluorescence intensity was 
detected with excitation and emission wavelengths of 485 nm and 535 nm in a 
Varioskan Flash microplate reader (Waltham, MA. USA). 
3.2.4 Mitochondrial ROS measurement 
The mitochondrial ROS was detected with MitoSOX
TM
 red mitochondrial 
superoxide indicator (Thermofisher, USA) in 96-well plate. After treatment, 
cells were washed with PBS and incubated with 5 µM MitoSOX
TM
 for 10 min 
at 37 ℃. The fluorescence intensity was detected with excitation and emission 
wavelengths of 510 nm and 580 nm in a Varioskan Flash microplate reader 
(Waltham, MA. USA). 
3.2.5 Hoechst 33342/propidium iodide staining 
Please refer to section 2.2.6.  
3.2.6 Lactate dehydrogenase assay 
Please refer to section 2.2.8. 
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3.2.7 Colony formation assay 
Colony formation using MCF-7 cells and HepG2 cells were assessed in 6 well 
plates. Briefly, 10,000 cells were seeded in triplicate in the presence of 
cisplatin (5 µM), GYY4137 (400 µM) or both for 7 days until colonies were 
readily visible. Colonies were then stained with crystal violet (5% w/v) for 15 
min. Subsequently, the plate was washed for 5 times with PBS. The 
representative pictures were captured using a scanner. 
3.2.8 Western blot assay 
Please refer to section 2.2.9. 
3.2.9 Animal models 
The therapeutic effects of NaSH and GYY4137 were evaluated in a mouse 
model of cisplatin nephrotoxicity. Specifically, C57BL/6J mice at 18-20 g 
were divided into 6 groups including control group (n=6), cisplatin group 
(n=9), NaSH + cisplatin group (n=9), GYY4137 + cisplatin group (n=9), 
NaSH alone group (n=6) and GYY4137 alone group (n=6). NaSH (5.6 mg/kg, 
in PBS) and GYY4137 (100 mg/kg, in PBS) were administrated by i.p. 
injection every 24 h for a total of 4 times. Cisplatin (25 mg/kg) was given by a 
single intraperitoneal (i.p.) injection 30 min after the second administration of 
NaSH or GYY4137. Mice from control group and cisplatin group were given 
with PBS instead of NaSH or GYY4137.   All the mice were sacrificed 24 h 
after the last dose of NaSH or GYY4137.  Blood and kidney were collected 
when the animals were sacrificed.   
3.2.10 Tag switch assay for S-sulfhydration 
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The S-sulfhydration of p47phox was detected with tag switch method as 
described previously [211]. Briefly, LLC-PK1 cells were treated with either 
100 µM NaSH for 30 min or 600 µM GYY4137 for 1 h. Thereafter, the cells 
were collected and lysed in HEN buffer (250 mM HEPES, 50 mM NaCl, 1 
mM EDTA, 0.1 mM neocuproine, 1% NP-40) containing protease inhibitors. 
The lysate was then mixed with 50 mM MSBT-A for 1 h in 37 ℃. After 
desalted, the mixture was incubated with protein A/G beads and anti-p47phox 
antibody overnight at 4 ℃. The beads were then resuspended in 20 mM biotin-
linked cyanoacetate in PBS and incubated at 37℃ for 1 h with gentle shaking. 
After centrifuge (3000 rpm, 5 min), the remaining beads were mixed with 30 
µL non-reducing loading buffer and boiled at 95℃ for 1 min, after which 
samples were analyzed with western blots. S-sulfhydration of p47phox was 
detected with anti-biotin antibody, while the total p47phox protein was 
determined with anti-p47phox antibody after stripping. 
3.2.11 Statistical analysis 
Please refer to section 2.2.11. 
 
3.3 Results 
3.3.1 H2S attenuates cisplatin induced RPT cell death 
The protective effect of endogenous H2S implies that exogenous H2S may also 
protect RPT cells from cisplatin induced cell death. Our result showed that 
H2S donor NaHS (50-200 µM) concentration dependently attenuated cisplatin 
induced LDH release (Figure 3-1A). To make sure the observed H2S effect 
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was not from H2S-cisplatin interaction [212], we compared the cytotoxic 
effects caused by cisplatin alone and the mixture of cisplatin+NaHS. Since 
cisplatin failed to elicit any cytotoxic effect after 24 h incubation at 37 
o
C 
(Figure 3-1B), the incubation time was shortened to 3-12 h, when most of H2S 
derived from NaHS have escaped from medium [108, 213]. It was found that 
the mixture displayed comparable cytotoxic effect with cisplatin alone (Figure 
3-1C). These results suggest that the action of H2S should be mainly from its 
cell protective effect rather than the reaction with cisplatin in our experimental 
condition. Thereafter, we proceeded to evaluate the protective effect of other 
H2S donors including GYY4137 and AP39 with concentration previously used 
by us and others in the literature [67, 211, 214]. As shown in Figure 3-1D&E, 
cisplatin (30 µM) led to increased release of LDH from RPT cells, which was 
attenuated by GYY4137 (200-600 µM) in a concentration-dependent manner. 
However, this was not observed with the mitochondria-targeted donor AP39 
(0.1-1 µM). Moreover, this result was reproduced by a CCK-8 assay showing 
that NaHS and GYY4137, but not AP39, mitigated the reduction of RPT cell 
viability caused by cisplatin (Figure 3-1F). Taken together, these results 
indicate that H2S donors NaSH and GYY4137, but not AP39, protect RPT 










Figure 3-1: H2S attenuated cisplatin induced RPT cell death. (A) LDH assay 
showed the effects of NaHS (pretreatment for 30 min) on cisplatin (30 µM, 24 h) 
induced RPT cell injuries. (B) 24 h incubation (37 
o
C and 5% CO2) led to inactivation 
of cisplatin. Specifically, 200 µM NaHS was pre-incubated in DMEM medium at 37 
o
C in cell culture plate for 30 min followed by addition of various concentrations of 
cisplatin. Then, the mixture was incubated at cell culture incubator (37 
o
C, 5% CO2) 
for another 24 h. (C) Effect of pre-incubation of NaHS with cisplatin on the 
cytotoxicity of cisplatin. In the pre-incubation group, 200 µM NaHS was first 
incubated at 37 
o
C for 30 min in cell culture plate followed by addition of 30 µM 





the fresh prepared group, 200 µM NaHS was added to the cells 30 min prior to the 
addition of cisplatin (30 µM). (D-E) Effect of GYY4137 (pretreatment for 60 min) 
and AP39 (pretreatment for 30 min) on cisplatin (30 µM, 24 h) induced RPT cell 
injuries by LDH assay. (F) Effect of NaHS (pretreatment for 30 min), GYY4137 
(pretreatment for 60 min) and AP 39 (pretreatment for 30 min) on cisplatin (30 µM, 















3.3.2 H2S suppresses cisplatin induced MAPKs activation in RPT cells 
Previous studies showed that cisplatin induced the activation of MAPKs which 
may contribute to subsequent RPT cell death [170]. Therefore, the effect of 
H2S donors NaSH and GYY4137 on MAPKs activation was examined. The 
results showed that cisplatin stimulated the phosphorylation of ERK, JNK and 
p38 in RPT cells (Figure 3-2A). However, pharmacological inhibition of ERK 
or JNK, but not p38, mitigated cisplatin caused RPT cell damage in the study 
(Figure 3-2B), implying that the activation of ERK and JNK, but not p38, is 
responsible for RPT cell death. Remarkably, both NaSH and GYY4137 
apparently diminished cisplatin induced the activation of MAPKs of all types 
(Figure 3- 2C, 2D, 2E &2F). These results indicate that exogenous H2S donors 
NaSH and GYY4137 protect RPT cells against cisplatin induced damage at 
















Figure 3-2: H2S suppressed cisplatin induced MAPKs activation in RPT cells. 
(A) Effect of cisplatin (30 µM) on the phosphorylation of ERK, JNK and p38 at 
various time points in LLC-PK1 cells. (B) Effects of PD (ERK inhibitor, 30 µM, 
pretreatment for 30 min), SP (JNK inhibitor, 10 µM, pretreatment for 30 min) and 
SB (p38 inhibitor, 10 µM, pretreatment for 30 min) on cisplatin (30 µM, 24 h) 
induced RPT cell injury. Effects of NaHS (C-D; 100 µM, pretreatment for 30 min) 
and GYY4137 (E-F; 600 µM, pretreatment for 60 min) cisplatin (30 µM, 12 h) 















3.3.3 H2S suppresses cisplatin induced ROS production in RPT cells 
Subsequently, the possible involvement of ROS in the process of cisplatin 
induced RPT cell death was examined. The result showed that the intracellular 
ROS was gradually increased upon cisplatin treatment (Figure 3-3A). The 
generation of mitochondrial ROS was also monitored with MitoSOX dye. 
However, cisplatin failed to induce mitochondrial ROS generation in 12 h, 
while 200 µM H2O2 as a positive control gradually increased mitochondrial 
ROS (Figure 3-3B). When NaSH or GYY4137 was supplemented, both of 
them obviously diminished cisplatin induced intracellular ROS generation 
(Figure 3-3C &3D). Since both NaSH and GYY4137 suppressed the 
activation of MAPKs and the generation of intracellular ROS, the relationship 
between these two events was therefore examined. The data showed that anti-
oxidant agent N-acetyl-cysteine (NAC) almost completely abolished MAPKs 
activation (Figure 3-3E &3F), implying it is the downstream of ROS 
generation. Taken together, these results suggest that exogenous H2S protects 
RPT cells from cisplatin induced death probably by suppressing ROS 













Figure 3-3: H2S suppressed cisplatin induced ROS production in RPT cells. 
Effect of cisplatin (30 µM) on the generation of intracellular ROS (A) and 
mitochondrial ROS (B) at various time points. 
***
p<0.001 versus time 0 for (A-B). 
NaHS (100 µM, pretreatment for 30 min) and GYY4137 (600 µM, pretreatment 
for 60 min) on cisplatin induced intracellular ROS generation detected by plate 
reader (C) and fluorescence microscope (D). Representative image from three 
independent experiments. (E-F) Effects of NAC (5 mM, pretreatment for 30 min) 
on cisplatin (30 µM, 12 h) induced phosphorylation of ERK, JNK and p38. 
***
p<0.001 versus control group; 
###




3.3.4 H2S suppresses cisplatin induced NADPH oxidase activation 
The possible involvement of NADPH oxidase in the protective effect of H2S 
was further tested. The results showed that cisplatin gradually increased the 
activity of NADPH oxidase in RPT cells (Figure 3-4A). Importantly, 
inhibition of NADPH oxidase with either diphenyleneiodonium (DPI) or 
apocynin largely attenuated cisplatin induced RPT cell damage (Figure 3-4B 
&4C), indicating a pivotal role of NADPH oxidase in the pathogenesis. 
Remarkably, NaSH and GYY4137 apparently mitigated cisplatin induced 
activation of NADPH oxidase (Figure 3-4D). These results indicate that H2S 
attenuates intracellular ROS generation and RPT cell death by suppressing the 
 
Figure 3-4: H2S suppressed cisplatin induced NADPH oxidase activation. (A) 





p<0.01 versus time 0. (B-C) Effect of Apocynin (200 µM, 
pretreatment for 30 min) and DPI (10 nM, pretreatment for 30 min) on cisplatin (30 
µM, 24 h) induced RPT cell injury. (D) Effects of NaHS (100 µM, pretreatment for 
30 min) and GYY4137 (600 µM, pretreatment for 60 min) on cisplatin (30 µM, 12 














activation of NADPH oxidase upon cisplatin treatment.   
3.3.5 H2S inhibits p47phox phosphorylation and induces its S-
sulfhydration  
Due to the pivotal role of p47phox in the assembly and subsequent activation 
of NADPH oxidase [215], the study thereafter examined the possible 
involvement of p47phox in cisplatin induced NADPH oxidase activation. The 
result showed that cisplatin time-dependently led to the phosphorylation of 
p47phox (Figure 3-5A). Importantly, NaSH and GYY4137 largely abolished 
p47phox phosphorylation, implying that H2S may suppress NADPH oxidase 
activity through inhibiting the phosphorylation of p47phox (Figure 3-5B). 
Intriguingly, it was found that the S-sulfhydration of p47phox was apparently 
increased upon the exposure of NaSH and GYY4137 (Figure 3-5C &5D). 
Taken together, the data suggest that H2S may inhibit cisplatin mediated 




















Figure 3-5: H2S inhibits p47phox phosphorylation and induces its S-
sulfhydration. (A) Effect of cisplatin (30 µM) on the phosphorylation of  
p47phox at various time points. 
*
p<0.05 versus time 0. (B) Effects of NaHS (100 
µM, 30 min) and GYY4137 (600 µM, 60 min) on cisplatin (30 µM, 8 h) induced 
phosphorylation of  p47phox. (C-D) NaHS (100 µM, 30 min) and GYY4137 (600 











3.3.6 H2S ameliorates cisplatin induced renal dysfunction and apoptosis 
Furthermore, the therapeutic effects of NaSH and GYY4137 against cisplatin 
nephrotoxicity were evaluated in mice. As indicated in Figure 3-6A &6B, the 
upsurge of blood creatinine and BUN led by cisplatin was significantly 
diminished with the treatment of either NaSH or GYY4137.  Consistently, the 
levels of cleaved caspase 8 and 3 were also apparently mitigated by H2S 
(Figure 3-6C &6D). These results suggest that exogenous H2S alleviates 
cisplatin induced renal dysfunction and apoptosis.  
 
Figure 3-6: H2S ameliorated cisplatin induced renal dysfunction and 
apoptosis. Effects of NaHS and GYY4137 on cisplatin induced increase of plasma 
creatinine (A) and BUN (B). (C-D) Effects of NaHS and GYY4137 on cisplatin 
















3.3.7 H2S does not compromise the anti-cancer activity of cisplatin in 
cancer cells 
The study also examined whether NaSH and GYY4137 would influence the 
anti-cancer activity of cisplatin within cancer cell lines. Prior to this, the effect 
of NaSH or GYY4137 on the cell viability was examined in a panel of cancer 
cell lines. The results showed that 100 µM NaSH failed to cause any changes 
on cell viability while GYY4137 at 600 µM significantly inhibits cancer cell 
growth after 5 days without affecting that of non-cancerous cells like WI-38 
and IMR90 (Figure 3-7A &7B). Moreover, NaSH was not found to influence 
the anti-cancer activity of cisplatin in HepG2 and MCF7 cells (Figure 3-7C 
&7D). Intriguingly, combination of GYY4137 and cisplatin caused more 
reduction of MTT compared with either compound alone in the two cancer 
cell lines (Figure 3-7E &7F), indicating that the combination produced 
stronger anti-cancer effect.  Additionally, this result was further confirmed 
with a colony formation assay showing that less colonies were formed when 
the cells were treated with GYY4137 and cisplatin compared with either 
compound alone (Figure 3-7G). These data suggest that NaSH and GYY4137 
do not compromise the anti-cancer activity of cisplatin in cancer cell lines like 










Figure 3-7: H2S did not compromise the anti-cancer activity of cisplatin in 
cancer cells. Effects of NaHS (A; 100 µM, 5 days) and GYY4137 (B; 600 µM, 5 
days) on the cell viability of cancerous cells (Hela, HCT116, HepG2 and MCF7) 
and noncancerous fibroblast cells (IMR90 and WI-38). 
***
p<0.001 versus control 
group. Effects of NaHS (100 µM, pretreatment with 30 min) on the anti-cancer 
activity of cisplatin (5 days) in MCF7 cells (C) and HepG2 cells (D). Effects of 
GYY4137 (600 µM, pretreatment with 60 min) on the anti-cancer activity of 





versus cisplatin group. (G) Effects of GYY4137 (400 µM, pretreatment with 60 
min) on the anti-cancer activity of cisplatin (7 days) in MCF7 cells and HepG2 






After revelation of the possible involvement of endogenous H2S in cisplatin 
nephrotoxicity, the study asked what could happen if exogenous H2S is 
provided into RPT cells upon cisplatin treatment. The results demonstrated 
that H2S donors namely NaSH and GYY4137 lessoned cisplatin caused RPT 
cell death.  Both the donors reduced the release of LDH and reduction of cell 
viability caused by cisplatin treatment. However, it was found that AP39, a 
mitochondrially targeted H2S donor, failed to produce any beneficial effect. 
When the generation of mitochondrial ROS was tested upon cisplatin 
treatment, the result showed that cisplatin did not induce mitochondrial ROS 
even at 12 h upon treatment. In line with this, a recent study showed that 
cisplatin failed to induce mitochondrial ROS generation in 12 h in primarily 
cultured RPT cells although it can lead to a significant increase of 
mitochondrial ROS in autophagy deficient RPT cells (Atg
-/- 
cells) [216]. These 
indicate that mitochondrial ROS may not be involved in cisplatin caused RPT 
cell death at least at early stages. In fact, most studies have demonstrated the 
protective effects of AP39 in conditions like ischemia/reperfusion which 
massively produces mitochondrial ROS and cell death [67, 198, 217]. 
Therefore, it is possible that AP39 fails to afford protective effect against 
cisplatin caused RPT cell death because mitochondrial ROS is not involved in 
cisplatin induced RPT cell injury.   
Thereafter, the study investigated the possible mechanisms underlying H2S 
mediated protective effect in RPT cells. The implication of MAPKs in the 
process was firstly examined due to their reported pivotal role in the disease 
[218, 219]. Similar with a previous study [171], the current study showed that 
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cisplatin treatment gradually led to the activation of MAPKs namely ERK, 
p38 and JNK which was largely suppressed by H2S donors namely NaSH and 
GYY4137. Moreover, it seems that H2S mediated protective effect in RPT 
cells may only involve ERK and JNK because pharmacological inhibition of 
ERK or JNK, but not p38, mitigated cisplatin caused RPT cell death. However, 
it is by no means to say that inhibition of p38 is not essential for the protective 
effect of H2S in vivo, as studies suggest that cisplatin induced activation of p38 
may promote inflammation which damages the kidney in animals [183, 218]. 
In addition, the inhibitory effect of H2S on all MAPKs implies that H2S may 
target the upstream event of MAPK activation.  
ROS production is one of the main forces driving RPT cell death upon 
cisplatin treatment [170, 171] and H2S is well recognized to possess anti-
oxidant effects [8], therefore the effect of H2S on cisplatin induced ROS 
generation was investigated. The results showed that NaSH and GYY4137 
reduced the generation of intracellular ROS significantly. Moreover, 
elimination of ROS with NAC abolished the activation of MAPKs of all types, 
indicating that the generation of intracellular ROS is the upstream event 
leading to MAPKs activation. Taken together, the data provided strong 
evidence that exogenous H2S donor NaSH and GYY4137 suppressed cisplatin 
induced ROS generation and the downstream MAPKs activation, therefore 
protecting RPT cells against cisplatin toxicity. This may also imply that 
cisplatin caused reduction of endogenous H2S may somehow boost 
intracellular ROS generation and thereby contribute to RPT cell death.  
Since the current results showed that mitochondrial ROS may not be involved 
in cisplatin induced RPT cell death, the possible involvement of NADPH 
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oxidase, another major source for intracellular ROS, was therefore examined 
[220]. The results showed that cisplatin activated NADPH oxidase. A recent 
study showed that pharmacological inhibition of NADPH oxidase protected 
against cisplatin induced nephrotoxicity in mice [175]. These results indicate 
that NADPH oxidase may be a promising therapeutic target for cisplatin 
induced renal toxicity. Interestingly, cisplatin induced activation of NADPH 
oxidase was significantly suppressed by NaSH and GYY4137. Therefore, it is 
likely that H2S inhibits the activation of NADPH oxidase and thereby affords 
protective effects in RPT cells.  
In fact, extensive evidence has suggested that NADPH oxidase may be a target 
of H2S [221, 222]; however, the underlying mechanisms remain largely 
elusive. The current study provided evidence showing that H2S suppressed 
cisplatin induced phosphorylation of p47phox which is critical for its 
membrane translocation [223]. One possible mechanism suggested by 
previous studies is that H2S mediated ERK inhibition suppressed the 
phosphorylation of p47phox [6]. However, the results showed that ERK 
activation should be the downstream of ROS generation upon cisplatin 
treatment and is therefore unlikely involved in H2S mediated inhibition of 
p47phox phosphorylation in the situation. In fact, extensive evidence has 
shown that NO and nitroxyl (a product of NO and H2S interaction) mediated 
S-nitrosylation of crucial thiol residues on p47phox inhibits the activity of 
NADPH oxidase [224, 225]. It was therefore hypothesized that H2S may be 
able to directly S-sulfhydrate p47phox. Using a tag-switch assay, the current 
results showed that NaSH and GYY led to significant S-sulfhydration of 
p47phox, indicating a direct interaction between H2S and p47phox. These 
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results may imply a novel mechanism underlying H2S mediated suppression of 
NADPH oxidase activity by directly S-sulfhydrating p47phox, although a 
definitive causality between the two events remains to be determined in the 
future. 
The protective effects of H2S against cisplatin nephrotoxicity were further 
demonstrated in mice models. Prior to the current research, a study reported 
that GYY4137 aggravated cisplatin induced renal damage by increasing 
inflammatory response [197]. However, several defects on the use of 
GYY4137 can be clearly identified in the study. For example, GYY4137 was 
prepared and stored in DMSO. This has been shown to be detrimental and 
accelerate GYY4137 decomposition [226]. Additionally, the study used a 
rather low dose of GYY4137 (21 mg/kg). It is likely that H2S might not be 
provided adequately considering the releasing property of H2S by the 
compound [68-71, 76]. Therefore, a relatively high yet commonly used dose 
of GYY4137 (100 mg/kg; prepared in PBS) was employed in the current 
animal study [76, 214]. For H2S acute releaser NaSH, a commonly used dose 
(5.28 mg/kg; prepared in PBS), was employed. At this dose, NaSH has been 
shown protective effect in renal diseases [35, 60, 200]. The data showed that 
administration of NaSH and GYY4137 largely ameliorated cisplatin caused 
renal dysfunction and damage with a clear reduction of apoptosis in renal 
cortex. These clearly suggest the protective effect of exogenous H2S against 
the cisplatin induced nephrotoxicity. 
When applying as a renal protective agent to alleviate cisplatin nephrotoxicity, 
it is essential to clarify whether the substance influences the anti-cancer 
activity of cisplatin.  Therefore, the anti-cancer activity of H2S donors and 
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combination with cisplatin was examined. In the study, lower concentrations 
of cisplatin and a longer time span were employed because it is believed that 
this will closely mimic the use of cisplatin for cancer therapy. The results 
showed that NaSH at 100 µM did not affect the cell viability in a panel of 
cancer cell lines and did not compromise the anti-cancer activity of cisplatin in 
cancer cell lines like MCF7 and HepG2. However, GYY4137 significantly 
suppressed cancer cell growth while sparing that of non-cancerous fibroblast 
cells like IMR90 and WI-38 which is consistent with previous reports [202-
206]. Intriguingly, combination of GYY4137 and cisplatin resulted in stronger 
anti-cancer effect in MCF7 and HepG2 as indicated with MTT and colony 
formation assay. These results indicate a promising therapeutic potential of 
H2S donors to treat cisplatin nephrotoxicity. However, more experiments are 
still needed to show whether these H2S donors would diminish the 
chemotherapeutic efficacy of cisplatin in tumor-bearing animal models in the 
future. 
In conclusion, the study in this chapter demonstrated that H2S donors like 
NaSH and GYY4137 ameliorated cisplatin caused renal toxicity in vitro and in 
vivo probably through suppressing the activation of NADPH oxdiase, 
downstream ROS generation and MAPKs activation. Importantly, GYY4137 
not only ameliorated cisplatin caused renal injury but also added on more anti-
cancer effect to cisplatin in cancer cell lines. Therefore, H2S should be a novel 









Polysulfides are a category of chemical compounds comprising chains of 
sulfur atoms. In mammalian system, polysulfides are generated from H2S as 
described in the following equation: 2nH2S + 1/2 (2n-1)O2     H2S2n + (2n-1) 
H2S in the presence of oxygen [127].  Intriguingly, besides directly derived 
from H2S, Kimura and others [130] demonstrated that they are also generated 
by H2S producing enzyme 3-mercaptopyruvate sulfurtransferase (3MST), 
implying its possible physiological importance. Although the biological 
functions of polysulfide are not fully acknowledged, current evidence tends to 
show that polysulfide may possess similar effect with H2S while with a higher 
potency. For example, Nagai et al. [132] found that polysulfides were able to 
activate TRPV channels more potently than H2S does. Subsequently, Oosumi 
and others [133] determined that Cysteine 422 and Cysteine 622 in the TRPV 
1 channel were sensitive to polysulfides.  The anti-oxidant effect of 
polysulfides was also studied recently. Koike and colleagues [135] initially 
reported that polysulfides exhibited protective effects against cytotoxicity 
caused by oxidative stress in neuroblastoma cells. Thereafter, they showed that 
polysulfides may activate the translocation of Nrf2 into nucleus by dimerizing 
keap1 which might facilitate the expression of anti-oxidant genes  [135]. 
Taken together, these results suggest that polysulfides may serve as a novel 
H2S derived signaling molecule in mammalian physiology and pathology. 
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 In the last two chapters, it was found that cisplatin treatment led to the 
reduction of H2S level which may contribute to the following RPT cell death 
and renal damage. Importantly, H2S donors namely NaSH and GYY4137 
largely attenuate cisplatin induced nephrotoxicity in mice, indicating its 
therapeutic potential in the disease. In the current chapter, it is aimed to 
examine the therapeutic potential of polysulfide in cisplatin nephrotoxicity and 
possible mechanisms involved. 
 
4.2 Materials and methods 
4.2.1 Cell culture  
Please refer to section 2.2.5. 
4.2.2 Cell viability assay 
Please refer to section 2.2.7. 
4.2.3 Intracellular ROS measurement 
Please refer to section 3.2.3. 
4.2.4 Hoechst 33342/propidium iodide staining 
Please refer to section 2.2.6.  
4.2.5 Lactate dehydrogenase assay 
Please refer to section 2.2.8. 
4.2.6 Western blot assay 
Please refer to section 2.2.9. 
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4.2.7 Animal models 
The therapeutic effects of Na2S4 were evaluated in rat model of cisplatin 
nephrotoxicity. Specifically, total 28 SD rats (200-220 g) were employed in 
the study. The rats were divided into 4 groups including control group (n=6), 
cisplatin group (n=8), Na2S4 + cisplatin group (n=8), Na2S4 group (n=6). 
Na2S4 (5.6 mg/kg, in saline) were administrated by i.p. injection every 24 h for 
a total of 7 times. Cisplatin (7 mg/kg) was given by a single intraperitoneal 
(i.p.) injection 30 min after the second administration of Na2S4. Rats from 
control group and cisplatin group were given with saline instead of Na2S4.   
All the rats were sacrificed 24 h after the last dose of Na2S4.  Serum and 
kidney were collected when the animals were sacrificed.   
4.2.8 Nuclear protein extraction 
The nuclear protein was extracted with NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (ThermoFisher) according to the manufacture’s 
instruction. Briefly, ice-cold CER I and CER II were used to extract the 
cytoplamsic proteins. Subsequently, NER reagent was employed to extract the 
nuclear proteins. The ratio of CER I: CER II: NER was maintained at 
200:11:100 µL respectively during the experiment. 
4.2.9 Statistical analysis 








4.3.1 Polysulfide attenuates cisplatin induced RPT cell death 
The protective effect of polysulfide was firstly examined within RPT cells. 
The results showed that at a concentration of 80 µM sodium tetrasulfide 
(Na2S4) almost completely abolished cisplatin caused LDH release which was 
only slightly reduced by sodium trisulfide (Na2S3) and hardly influenced by 
sodium disulfide (Na2S2) (Figure 4-1A).  Therefore, Na2S4 was used as a 
polysulfide donor in the following studies. The protective effect of Na2S4 was 
confirmed by a concentration-dependent assay as shown in Figure 4-1B and 
Hoechst/PI staining (Figure 4-1C& 1D) in which 80 µM Na2S4 largely 
reduced the PI positive cell numbers caused by cisplatin. Moreover, Na2S4 
also reversed cisplatin induced cleavage of caspase 3 (Figure 4-1E). These 







Figure 4-1: Polysulfide attenuated cisplatin induced RPT cell death. (A) 
Effects of polysulfide donors (80 µM, pretreatment for 30 min) on cisplatin (30 
µM, 24 h) induced  LDH release.  (B) Effect of Na2S4 (pretreatment for 30 min) 
on cisplatin (30 µM, 24 h) induced LDH release. (C-D) Hoechst/PI staining 
assay showed that Na2S4 (80 µM, pretreatment for 30 min) attenuated cisplatin 
(30 µM, 24 h) induced RPT cell death. (E) Effect of polysulfide (80 µM, 
pretreatment for 30 min) on cisplatin induced cleavage of caspase 3 (30 µM, 24 
h). 
***




p<0.001 versus cisplatin group. 




4.3.2 Polysulfide suppresses cisplatin induced ROS generation and 
MAPKs activation in RPT cells 
As shown in Figure 4-2A& 2B, cisplatin induced massive production of 
intracellular ROS which was apparently suppressed by the pretreatment of 
Na2S4. Importantly, elimination of ROS by N-acetyl-cysteine (NAC) almost 
completely blocked cisplatin caused cleavage of caspase 3 (Figure 4-2C). 
These results indicate that the protective effect of polysulfide is at least 
partially due to the suppression of intracellular ROS production. The study 
also examined the involvement of MAPKs in the protective effect of 
polysulfide. The results showed that cisplatin led to the phosphorylation of 
MAPKs of all types which was largely abolished by Na2S4 (Figure 4-2D, 2E& 
2F). These data suggest that the protective effect of polysulfide involves its 














Figure 4-2: Polysulfide suppressed cisplatin induced ROS production and 
MAPKs activation in RPT cells. Na2S4 (80 µM, pretreatment for 30 min) on 
cisplatin induced intracellular ROS generation detected by plate reader (A) and 
fluorescence microscope (B). (C) Effect of NAC (5 mM, pretreatment for 30 min) 
on cisplatin induced cleavage of caspase 3 in RPT cells. (D-F) Effects of Na2S4 
(80 µM, pretreatment for 30 min) on cisplatin (30 µM, 12 h) induced 













4.3.3 Polysulfide inhibits cisplatin induced NADPH oxidase activation 
The effect of Na2S4 on the activity of NADPH oxidase was examined 
thereafter. The results showed that Na2S4 apparently inhibited cisplatin 
induced activation of NADPH oxidase (Figure 4-3A). The study also 
examined whether Na2S4 influenced cisplatin mediated phosphorylation of 
p47phox. As shown in Figure 4-3B, the phosphorylation of p47phox was 
obviously suppressed by the pretreatment of Na2S4. These results imply that 
polysulfide may inhibit cisplatin induced NADPH oxidase activation by 





Figure 4-3: Polysulfide inhibited cisplatin induced NADPH oxidase activation. 
(A) Na2S4 (80 µM, pretreatment for 30 min) suppressed cisplatin (30 µM, 12 h) 
induced NADPH activity. (B) Na2S4 (80 µM, pretreatment for 30 min) suppressed 













4.3.4 Polysulfide induces nucleus translocation of Nrf2  
Previous studies showed the involvement of Keap1/Nrf2 pathway in the anti-
oxidant effect of polysulfide  [135]. The possible participation of the pathway 
was therefore investigated. The results showed that polysulfide apparently led 
to the accumulation of Nrf2 in nucleus without causing any obvious changes 
on the total Nrf2 (Figure 4-4A-C). The nucleus translocation of Nrf2 is able to 
enhance the anti-oxidant capacity of cells and therefore affords protective 




Figure 4-4: Polysulfide induced nucleus translocation of Nrf2. Effect of Na2S4 
(80 µM) on total expression of Nrf2 and nucleus level of Nrf2 (A-C). 
*
p<0.05 





4.3.5 Polysulfide mediated nucleus translocation of Nrf2 involves AKT 
and Keap1 dimmerization 
The study further examined the possible mechanisms underlying polysulfide 
mediated nucleus translocation of Nrf2. The results showed that polysulfide 
led to the phosphorylation of AKT in RPT cells (Figure 4-5A). Importantly, 
pharmacological inhibition of AKT activation not only attenuated nucleus 
translocation of Nrf2 but also lessened the protective effect of polysulfide 
(Figure 4-5B& 5C). Moreover, the data showed that polysulfide caused the 
dimmerization of Keap1 (Figure 4-5D), which may also induce the release of 







Figure 4-5: Polysulfide mediated nucleus translocation of Nrf2 involved AKT 
and keap1 dimmerization. (A) Effect of Na2S4 (80 µM) on the phosphorylation of 
AKT. Effect of LY (AKT inhibitor LY294002, 15 µM, pretreatment for 15 min) on 
Na2S4 (80 µM, 1 h) mediated nucleus translocation of Nrf2 (B) and cell protection 




















4.3.6 Polysulfide mitigates cisplatin induced renal dysfunction and renal 
apoptosis 
Furthermore, the therapeutic effects of polysulfide against cisplatin 
nephrotoxicity were evaluated in rats. As indicated in Figure 4-6A& 6B, the 
upsurge of blood creatinine and BUN led by cisplatin was diminished with the 
treatment of polysulfide.  Consistently, the levels of cleaved caspase 9 and 3 
are also apparently mitigated by polysulfide Figure 4-6C &6D. These results 
suggest that polysulfide alleviates cisplatin induced renal dysfunction and 
renal cortical apoptosis. 
 
 
Figure 4-6: Polysulfide ameliorated cisplatin induced renal dysfunction and 
apoptosis. Effects of Na2S4 on cisplatin induced increase of plasma creatinine (A) 
and BUN (B). (C-D) Effects of Na2S4 on cisplatin induced cleavage of caspase 9 






p<0.001  versus control 
group; 
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4.3.7 Polysulfide inhibits cell growth in non-small cell lung cancer cell 
lines  
The effect of polysulfide donors (Na2S2, Na2S3 and Na2S4) on the cell viability 
was further tested in a panel of non-small cell lung cancer (NSCLC) cell lines. 
The results showed that polysulfides significantly inhibited cancer cell growth 
after 24 h without affecting that of non-cancerous lung fibroblast cells like 
WI-38 (Figure 4-7A, 7B& 7C). Interestingly, their IC50 values indicate that 
the more sulfur atoms polysulfide contains the higher anti-cancer effect it may 
induce (Figure 4-7D).  These results indicate that polysulfide possesses anti-
cancer activity in NSCLC cell lines. 
 
 
Figure 4-7: Polysulfide inhibited cell growth in non-small cell lung cancer cell lines. 
(A-C) Effect of Na2S4 on the cell viability of NSCLC cell lines and WI-38 after treatment 




4.3.8 Polysulfide does not compromise the anti-cancer activity of cisplatin 
in NSCLC cell lines 
Subsequently, the effect of Na2S4 on the anti-cancer activity of cisplatin was 
evaluated in NSCLC cell lines A549 and H1299. The results showed that 
Na2S4 did not exhibit any apparent influence on cisplatin induced reduction of 
A549 cell viability (Figure 4-8A& 8B). Intriguingly, it added more anti-cancer 
activity to cisplatin in H1299 (Figure 4-8D& 8E). These data suggest that 
polysulfide may not compromise the anti-cancer activity of cisplatin at least in 
NSCLC cell lines. 
 
 
Figure 4-8: Polysulfide did not compromise the anti-cancer activity of 
cisplatin in NSCLC cell lines. Effect of Na2S4 (80 µM, pretreatment for 30 min) 









p<0.001 versus non-treated 









In chapter III, it was found that H2S donors protect RPT cells and kidney 
against cisplatin caused damage. Therefore, the current chapter aimed to 
examine whether polysulfide, an H2S derived signaling molecule, possesses 
renal protective effect in cisplatin nephrotoxicity and mechanisms involved.  
Polysulfides are a category of chemical compounds comprising chains of 
sulfur atoms. There are two main classes of polysulfides reported namely 
anions and organic polysulfides [126]. Anions have the general formula Sn
2-
 
which is the chemical basis of hydrogen polysulfides H2Sn and sodium 
polysulfides Na2Sn. Organic polysulfides, such as garlic derived diallyl 
disulfides (DADS) and diallyl trisulfides (DATS), usually possess a formula 
of RSnR where R is either an alkyl or aryl group. In this study, we have 
employed sodium polysulfides Na2Sn as donors because they solely provide 
Sn
2- 
in aqueous solutions and therefore should be able to more closely mimic 
the endogenous produced polysulfides as reported previously [207].  
RPT cell injuries lead to subsequent nephrotoxicity upon cisplatin treatment 
[177]; therefore, the protective effect of polysulfide was firstly tested within 
RPT cells. The beneficial effect of polysulfide donor Na2S4 was demonstrated 
with the evidence that it apparently mitigated cisplatin caused LDH release, 
increase of PI positive cell numbers and activation of apoptotic pathways. The 
study also compared the protective effects of distinct polysulfide donors 
including Na2S2, Na2S3 and Na2S4. Intriguingly, the results suggest that the 
more sulfur atoms polysulfide contains the higher protective effect it may 
induce. Therefore, Na2S4 was employed as the polysulfide donor in the current 
research as it elicited the strongest effects. Meanwhile, it is reasonable to 
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speculate that polysulfide donors containing over 4 sulfur atoms may possess 
stronger renal protective effect which warrants further studies in the future.  
 Thereafter, the possible mechanisms underlying the protective effect of 
polysulfide were investigated in RPT cells. The axis of intracellular ROS and 
MAPKs plays a critical role in cisplatin induced RPT cell injuries, which is 
also involved in the protective effect of H2S. The possible implication of this 
axis herein was therefore examined. The current study showed that polysulfide 
largely attenuated cisplatin induced production of intracellular ROS. As a 
result, the following activation of MAPKs was also suppressed upon the 
supplementation of polysulfide. Since elimination of ROS almost completely 
abolished cisplatin induced RPT cell apoptosis, it is reasonable to ascribe the 
protective effect of polysulfide at least partially to its antioxidant capability. 
Therefore, the possible signaling mechanisms involved in the anti-oxidant 
effect of polysulfide were subsequently studied. NADPH oxidase was firstly 
examined as it plays a pivotal role in cisplatin induced nephrotoxicity [227, 
228] and is suggested to be a target of H2S [8]. The results displayed a 
suppressive effect of polysulfide on the activation of NADPH oxidase induced 
by cisplatin. Moreover, this effect was further attributed to its suppressive 
effect on p47phox phosphorylation which is a critical event for the assembly 
of NADPH oxidase [220, 221]. However, the existence of direct interaction 
between polysulfide and p47phox remains to be determined in the future. 
Similar with a previous study, the current study further showed that 
polysulfide may induce the translocation of Nrf2 and thereby contribute to its 
suppressive effect on intracellular ROS production. Taken together, these data 
suggest that polysulfide inhibits cisplatin caused intracellular ROS generation 
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by suppressing NADPH oxidase activation and promoting Nrf2 nucleus 
translocation simultaneously upon cisplatin treatment in RPT cells. 
Following this, evidence was further provided to illustrate the mechanisms 
underlying polysulfide induced Nrf2 nucleus translocation. Phosphorylation of 
Nrf2 by AKT is known to facilitate its nucleus translocation [229]. The current 
results showed that polysulfide significantly induced the activation of AKT 
while pharmacological inhibition of AKT attenuated polysulfide induced Nrf2 
nucleus translocation and protective effect in RPT cells. These data suggest 
that polysulfide mediated Nrf2 translocation is at least partially due to the 
activation of AKT. Besides, a previous study showed that polysulfide can 
induce the dimmer formation of Keap1 in neuronal cells which may also 
contribute to the following Nrf2 nucleus translocation [135]. However, the 
underlying mechanisms involved are not clear. It was found here that 
polysulfide is also able to induce the dimer formation of Keap1 in RPT cells. 
A previous study showed that H2S mediated S-sulfhydration of cysteine-151 
on Keap1 may induce the release of Nrf2 [230]. Therefore, it is reasonable to 
speculate that S-sulfhydration of Keap1 on cysteine-151 by polysulfide 
triggers its dimer formation which results in the release of Nrf2 and following 
nucleus translocation. This part of work is still ongoing. 
The protective effect of polysulfide was further demonstrated in the animal 
models. Using a similar dose of H2S donor NaSH (5.6 mg/kg) that elicited 
protective effects in cisplatin nephrotoxicity, it was found that polysulfide 
apparently ameliorated cisplatin caused renal dysfunction and damage with a 
clear reduction of apoptosis in renal cortex. These clearly suggest the 
protective effect of exogenous polysulfide against cisplatin induced 
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nephrotoxicity. Since the efficacy of polysulfide donors with various numbers 
of sulfur atoms was not compared in the current study, whether sulfur numbers 
in polysulfide correlate to the in vivo efficacy remains elusive and should be 
determined in the future.   
When applying as a renal protective agent to treat cisplatin induced 
nephrotoxicity, it is necessary to clarify whether the substance influences the 
anti-cancer activity of cisplatin.  Therefore, the anti-cancer activity of 
polysulfide donors and combination with cisplatin were examined. The anti-
cancer activity of polysulfide donors (Na2S2, Na2S3 and Na2S4) was firstly 
examined and compared in NSCLC cell lines. The current data showed that 
polysulfide donors significantly suppressed cancer cell growth while sparing 
that of non-cancerous fibroblast cell WI-38. Interestingly, the numbers of 
sulfur atoms well reflects its anti-cancer activity, which is consistent with the 
protective effect in RPT cells. Additionally, combination of polysulfide donor 
Na2S4 and cisplatin resulted in stronger anti-cancer effect in NSCLC cell lines 
like H1299 and A549 indicated with MTT. These results indicate a promising 
therapeutic potential of polysulfide to treat cisplatin nephrotoxicity. However, 
more experiments are still needed to show whether polysulfide would 
influence the chemotherapeutic efficacy of cisplatin in tumor-bearing animal 
models in the future. 
In conclusion, the study in this chapter provided a comprehensive 
understanding about the therapeutic potential of polysulfide in cisplatin 
nephrotoxicity and possible mechanisms involved. The results indicate that 
polysulfide donor Na2S4 ameliorated cisplatin caused renal toxicity in vitro 
and in vivo probably through suppressing intracellular ROS generation and 
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downstream MAPKs activation. Additionally, polysulfide may inhibit ROS 
production by lessening the activation of NADPH oxidase and induction of 
Nrf2 nucleus translocation simultaneously in RPT cells. Importantly, 
polysulfide not only ameliorated cisplatin caused renal injury but also added 
on more anti-cancer effect to cisplatin in NSCLC cancer cell lines. Importantly, 
the results also showed that the number of sulfur atoms in polysulfide well 
reflects the efficacy of these molecules not only in cell protection but also 
cancer inhibition which may serve as a guide for further development of 
polysulfide donors for pharmaceutical usage. Based on the current study, 
polysulfide may be a novel and promising therapeutic target for the treatment 













Chapter V General discussion 
 
The current research aimed to explore the role and therapeutic potential of H2S 
and polysulfide in cisplatin nephrotoxicity. The study provided strong 
evidence demonstrating the possible involvement of endogenous H2S in the 
pathogenesis of cisplatin nephrotoxicity and the therapeutic value by targeting 
H2S and polysulfide for its treatment. This chapter serves to discuss the 
implications of the results and further studies warranted.  
5.1 Role of endogenous H2S and polysulfide in cisplatin nephrotoxicity 
The production of H2S is precisely controlled in kidney by an enzymatic 
system as showed in Figure 1-1. Nevertheless, changed expression levels of 
these H2S producing enzymes were often found in various pathological 
conditions, which lead to altered levels of endogenous H2S [8, 30]. 
Intriguingly, the alternation contributes to the progression of diseases such as 
renal IRI and diabetic nephropathy [8, 30] perhaps due to significant roles of 
H2S not only in renal physiology but also in the maintenance of cellular 
homeostasis [129, 231]. Prior to this study, the role of endogenous H2S was 
not known in cisplatin nephrotoxicity, although evidence suggests the reduced 
mRNA levels of CSE and CBS [197]. This study, for the first time, 
demonstrated the reduction of endogenous H2S levels due to the reduced 
expression of CSE, but not CBS, upon cisplatin treatment. Nevertheless, the 
possible mechanisms of this reduction remain unclear. Intriguingly, the current 
study also found that production of endogenous H2S is protective against 
cisplatin induced RPT cell death by overexpressing CSE or adding H2S 
producing substrates in RPT cells. These results suggest that reduction of 
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endogenous H2S may contribute to cisplatin induced RPT cell injury. To 
consolidate this conclusion, further studies are required such as examining 
whether CSE deficiency worsens cisplatin nephrotoxicity in animals. 
Moreover, how the reduction of endogenous H2S influence the disease 
progression may also need to be explored in the future. 
Hydrogen polysulfide is a newly founded endogenous molecule derived from 
H2S. Although evidence suggests that it can be synthesized by H2S producing 
enzyme 3MST, the portion of polysulfide derived from this pathway remains 
unclear. Moreover, the measurement of endogenous hydrogen polysulfide in 
biological samples is extremely difficult due to the abundance of other types 
of polysulfide such as organic polysulfide [207]. Therefore, the role of 
endogenous hydrogen polysulfide was not explored in the current study. 
Nevertheless, the reduction of endogenous H2S implies that cisplatin may also 
reduce the level of endogenous hydrogen polysulfide as H2S at least partially 
serves as a source of hydrogen polysulfide in mammals. This needs to be 
demonstrated in the future.  
5.2 Donation of H2S or polysulfide for cisplatin nephrotoxicity treatment 
Although H2S donation exhibits broad protective effects in multiple organs, 
the therapeutic value of the strategy is controversial in the context of cisplatin 
nephrotoxicity. For example, a study reported that H2S slow releaser 
GYY4137 aggravated cisplatin induced renal damage by increasing 
inflammatory response [197]. However, several defects on the use of 
GYY4137 can be clearly identified in the study. For example, GYY4137 was 
prepared and stored in DMSO. This has been shown to be detrimental and 
accelerate GYY4137 decomposition [226]. Therefore, it is possible that the 
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decomposed product of GYY4137 aggravated cisplatin induced renal damage 
when solved in DMSO. Additionally, the study used a rather low dose of 
GYY4137 (21 mg/kg). It is likely that H2S might be not provided adequately 
considering the releasing property of H2S by the compound [68-71, 76]. 
Therefore, this study used several distinct H2S donors namely H2S acute 
releaser NaSH, H2S slow releaser GYY4137 and H2S mitochondrial releaser 
AP39 in parallel to demonstrate the protective effect of H2S. Moreover, a 
relatively high yet commonly used dose of GYY4137 (100 mg/kg; prepared in 
PBS) was used in the animal study [76, 214]. The current study provided 
compelling evidence showing the protective effect of H2S in in vitro and in 
vivo models. Importantly, the anti-cancer agent GYY4137 adds on more anti-
cancer activity to cisplatin in some cancer cell lines, indicating its potential for 
the therapy of cisplatin nephrotoxicity. However, more experiments are still 
needed to show whether these H2S donors would diminish the 
chemotherapeutic efficacy of cisplatin in tumor-bearing animal models in the 
future. 
Similar with H2S, polysulfide also exhibited strong renal protective effect in 
cisplatin nephrotoxicity without compromising its anti-cancer activity in 
NSCLC cell lines. Remarkably, it was observed that that the number of sulfur 
atoms in polysulfide well reflects the efficacy of these molecules not only in 
cell protection but also cancer inhibition. This may serve as a guide for further 
development of polysulfide donors for pharmaceutical usage. Nevertheless, 
the current study only used the acute releaser of polysulfide namely sodium 
polysulfide. Therefore, more types of polysulfide donors are warranted to be 
developed and studied in the future. 
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5.3 H2S and polysulfide mediated anti-oxidant effect 
Due to the pivotal of ROS in the pathogenesis of cisplatin nephrotoxicity [177], 
we mainly examined the anti-oxidant effects mediated by H2S and polysulfide. 
The results indicate that these two types of molecules share similar 
mechanisms in suppressing intracellular ROS generation. Firstly, they 
suppressed the activation of NADPH oxidase. In fact, emerging evidence 
suggests that NADPH oxidase is a potential target of H2S [8]. Intriguingly, it 
was showed that NO and nitroxyl (a product of NO and H2S interaction) 
mediated S-nitrosylation of crucial thiol residues on p47phox inhibits the 
activity of NADPH oxidase [224, 225]. It was therefore hypothesized that H2S 
may be able to directly S-sulfhydrate p47phox. Using a tag-switch assay, the 
results showed that NaSH and GYY led to significant S-sulfhydration of 
p47phox, indicating a direct interaction between H2S and p47phox. These 
results may imply a novel mechanism underlying H2S mediated suppression of 
NADPH oxidase activity by directly S-sulfhydrating p47phox, although a 
definitive causality between the two events and the cysteine residues targeted 
by H2S and polysulfide remains to be determined in the future. Besides, the 
data also indicate the involvement of nucleus translocation of Nrf2. A previous 
study demonstrated that H2S mediated S-sulfhydration of Keap1 at cysteine-
151 triggers the release and nucleus translocation of Nrf2 [135]. Here it was 
found that polysulfide mediated nucleus translocation of Nrf2 at least involves 
AKT activation. The current study also showed that polysulfide induced the 
dimmer formation of Keap1. However, whether this leads to the following 
release of Nrf2 remains to be determined. 
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5.4 H2S and polysulfide mediated anti-cancer effect 
In contrast to toxic chemotherapeutic drugs, H2S possesses protective effect in 
multiple organs even in the doses that are able to inhibit tumor growth as 
shown with the slowly releasing donor GYY4137 [214, 232, 233]. On top of 
this, H2S is shown to affect multiple targets and therefore has far-reaching 
effects in mammalian cells. Thus, it is likely that the existence of H2S is 
critical for the maintenance of cellular homeostasis including both normal 
cells and cancer cells.  This is supported by the evidence that H2S is essential 
to regulate the homeostasis of redox [234] and thiols [235].  Thus, modulation 
of H2S may disrupt the cellular homeostasis of cancer as a whole and thereby 
lead to the subsequent death. Perhaps due to this, H2S based therapy has been 
demonstrated to be effective in multiple cancer types [107, 108]. Importantly, 
the distinct level of endogenous H2S in cancerous and non-cancerous cells 
might afford them the different tolerances to H2S supplementation or H2S 
inhibition. This has been indicated by the demonstrated therapeutic window of 
H2S based approach for cancer therapy [107, 108]. Additionally, H2S gas is 
highly lipophilic which allows it freely penetrate into the cell membrane of all 
types and become biologically active [236]. This may at least have two 
implications: (a) H2S may have significant influence on tumor 
microenvironment which has shown to be important for tumor progression 
[237]; (b) it may be able to readily infiltrate into solid tumor. Therefore, 
although still in its infancy, H2S based therapy may represent a novel and 
unique strategy for cancer treatment. 
Besides, it was found here that polysulfide also possessed cell protection and 
anti-cancer activity. Importantly, at doses eliciting cell protective effect, it 
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apparently suppresses cancer cell growth. Therefore, polysulfide may also 
represent a novel strategy for cancer treatment which warrants further studies. 
5.5 The interrelationship between H2S and polysulfide in mammals 
H2S is a very short lived molecule; however, numerous studies have shown the 
long lasting biological effects of H2S in mammalian systems. Therefore, it is 
reasonable to speculate whether the formation of certain more stable 
substance(s) accounts for H2S derived effects. Kimura’s group identified 
polysulfides in the solution of NaSH [238]. Intriguingly, compared with NaSH, 
the polysufides (Na2S2, Na2S3 and Na2S4) elicit much stronger effects on the 
activation of TRPA1 in rat astrocytes [133] and activation of Keap1/Nrf2 in 
neuronal cells [135]. The existence of endogenous polysulfides has also been 
demonstrated by that group [239]. Therefore, it is gradually recognized that 
polysulfide may be the active entity mediated H2S signaling. However, 
examination of the processes of hydrogen polysulfide formation, one can 
clearly observe that H2S can also be released from hydrogen polysulfide. 
Therefore, it is proposed here that there is an interchange between H2S and 
hydrogen polysulfide in mammalian systems depending on the cellular 
oxidative state.  For example, oxidation increases the formation of polysulfide 
from H2S and vice versa. Due to the interchange and co-existence, therefore 
H2S and polysulfide share similar biological activities.  However, why 
polysulfide is more potent than H2S as indicated by most studies? Herein it is 
speculated that one of the reasons could be that polysulfide can directly S-
sulfhydrate R-SH group whereas H2S can only S-sulfhydrate oxidized thiols 
namely R-SOH group (In cells, the proportion of R-SH group should be larger 
than R-SOH group). And perhaps increase of sulfur atoms in polysulfide can 
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enhance its S-sulfhydration capacity; therefore polysulfide with more sulfur 
atoms elicits more potent biological effects as indicated by the current study. 
Further studies are required to better understand the interrelationship between 
H2S and polysulfide which will greatly enhance the knowledge and shed light 













Chapter VI Conclusion remarks 
 
In conclusion, this study provided a comprehensive understanding about the 
role and therapeutic potential of H2S and polysulfide in cisplatin 
nephrotoxicity. The results indicate that cisplatin led to the reduction of 
endogenous H2S which may be implicated in the following RPT cell death and 
nephrotoxicity. Interestingly, H2S donors like NaSH and GYY4137 
ameliorated cisplatin caused renal toxicity in vitro and in vivo probably 
through suppressing the activation of NADPH oxidase, downstream ROS 
generation and MAPKs activation. Importantly, GYY4137 not only 
ameliorated cisplatin caused renal injury but also added on more anti-cancer 
effect to cisplatin in cancer cell lines. Moreover, the current study also showed 
that polysulfide donor Na2S4 ameliorated cisplatin caused renal toxicity in 
vitro and in vivo probably through suppressing intracellular ROS generation 
and downstream MAPKs activation. Additionally, polysulfide may inhibit 
ROS production by inhibiting the activation of NADPH oxidase and induction 
of Nrf2 nucleus translocation simultaneously in RPT cells. Importantly, 
polysulfide not only ameliorated cisplatin caused renal injury but also added 
on more anti-cancer effect to cisplatin in NSCLC cancer cell lines. 
Additionally, the present study also showed that the number of sulfur atoms in 
polysulfide well reflects the efficacy of these molecules not only in cell 
protection but also cancer inhibition which may serve as a guide for further 
development of polysulfide–related drugs. Based on the current study, H2S 
and polysulfide may be novel and promising therapeutic targets for the 
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